Any feedback?
Information on EC 2.7.11.30 - receptor protein serine/threonine kinase and Organism(s) Homo sapiens and UniProt Accession P36897
for references in articles please use BRENDA:EC2.7.11.30Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.7.11.30 receptor protein serine/threonine kinaseIUBMB Comments
The transforming growth factor beta (TGF-beta) family of cytokines regulates cell proliferation, differentiation, recognition and death. Signalling occurs by the binding of ligand to the type II receptor, which is the constitutively active kinase. Bound TGF-beta is then recognized by receptor I, which is phosphorylated and can propagate the signal to downstream substrates [1,3].
Specify your search results
Word Map
- 2.7.11.30
-
necroptosis
- pulmonary
- arterial
- hypertension
- endothelial
- smads
- tgf-beta1
- necrosis
- mlkl
- hereditary
- tnf
- fibrosis
- telangiectasia
-
hemorrhagic
- endoglin
- collagen
- malformation
-
arteriovenous
- caspase-8
-
idiopathic
-
domain-like
-
smad2/3
-
tgf-beta-induced
- osteoblast
- factor-beta1
- myofibroblasts
-
tgf-beta-mediated
-
necrostatin-1s
- bmp2
-
autocrine
- epistaxis
- fadd
- bmpr1a
-
tnf-induced
-
anaplastic
-
pseudokinase
-
heteromeric
-
serine-threonine
-
pasmcs
- tak1
- noggin
-
smad-dependent
-
mucocutaneous
- monocrotaline
- tgfbr1
- medicine
-
fkbp12
-
mixed-lineage
- pharmacology
-
receptor-regulated
- ciap2
- diagnostics
-
alk-positive
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
The enzyme appears in selected viruses and cellular organisms
Synonyms
ripk1, bmpr2, ripk3, tgf-beta receptor, tbetarii, alk-1, acvrl1, bmpr-ii, bmprii, tbetar-ii, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
ALK5
activin receptor-like kinase 1
activin receptor-like kinase 7
ALK1
ALK7
ESK2
-
-
-
-
MIS type II receptor
-
-
-
-
MISRII
-
-
-
-
MRII
-
-
-
-
Serine/threonine-protein kinase receptor R1
-
-
-
-
Serine/threonine-protein kinase receptor R4
-
-
-
-
Serine/threonine-protein kinase receptor R5
-
-
-
-
Serine/threonine-protein kinase receptor R6
-
-
-
-
SKR1
-
-
-
-
SKR2
-
-
-
-
SKR3
-
-
-
-
SKR4
-
-
-
-
SKR5
-
-
-
-
SKR6
-
-
-
-
TGF-beta type I receptor
TGF-beta type II receptor
-
-
-
-
TSK-7L
-
-
-
-
additional information
-
ALK7 is a type I serine/threonine kinase receptor belonging to the TGF-beta family of proteins
TGF-beta type I receptor
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
ATP:[receptor-protein] phosphotransferase
The transforming growth factor beta (TGF-beta) family of cytokines regulates cell proliferation, differentiation, recognition and death. Signalling occurs by the binding of ligand to the type II receptor, which is the constitutively active kinase. Bound TGF-beta is then recognized by receptor I, which is phosphorylated and can propagate the signal to downstream substrates [1,3].
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
146702-86-5
-
152060-53-2
-
154907-75-2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
ATP + KMGSPSVRCS(P)SMS
ADP + ?
TGF-beta-induced phosphorylation by TbetaRI receptor kinase of the Smad2-derived, phosphorylated peptide substrate containing Ser465 phosphorylation site, poor activity with nonphosphorylated peptide substrate
-
-
?
ATP + [TGF-beta receptor I]
ADP + [TGF-beta receptor I] phosphate
-
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
TGF-beta-induced phosphorylation by TbetaRI receptor kinase at both phosphorylation sites Ser465 and Ser467 leads to release of Smad2 from membrane-anchored protein SARA and signaling co-mediator Smad4, translocation into the nucleus, and regulation of target gene expression
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
TGF-beta-induced phosphorylation by TbetaRI receptor kinase at two phosphorylation sites Ser465 and Ser467 within the MH2 domain, activity with Smad2 analogues, overview
-
-
?
ATP + Smad
ADP + phosphorylated Smad
-
involved in ALK5 activation of p38 MAPK signaling and of GADDbeta45 and BGN expression induced by TGF-beta
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
step in the MAPK signaling pathway via JNK and p38
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
TGF-beta- or actividin-induced phosphorylation
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
TGF-beta-mediated activation of Smad2 by the TGF-beta receptor
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
recombinant GST-fusion Smad2 substrate expressed in Escherichia coli, TGF-beta- or actividin-induced phosphorylation of the two C-terminal Ser residues in the Ser-Ser-Xaa-Ser motif
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
the substrate is a tumor suppressor
-
-
?
ATP + Smad3
ADP + phosphorylated Smad3
-
step in the MAPK signaling pathway via JNK and p38
-
-
?
ATP + Smad3
ADP + phosphorylated Smad3
-
TGF-beta-mediated activation of Smad3 by the TGF-beta receptor
-
-
?
ATP + Smad3
ADP + phosphorylated Smad3
-
the substrate is a tumor suppressor
-
-
?
ATP + [actividin receptor]
ADP + [actividin receptor] phosphate
-
-
-
-
?
ATP + [actividin receptor]
ADP + [actividin receptor] phosphate
-
activins regulate pancreatic development, differentiation and insulin secretion, insulin gene is a target in activin receptor-like kinase 7 signaling pathway in pancreatic beta-cells, SBE and A/GG elements of the human insulin promoter are involved in the regulation of the ALK7 signal, regulation, overview
-
-
?
ATP + [TGF-beta receptor II]
ADP + [TGF-beta receptor II] phosphate
-
regulation and metabolism, overview
-
-
?
ATP + [TGF-beta receptor I]
ADP + [TGF-beta receptor I] phosphate
-
-
-
-
?
ATP + [TGF-beta receptor I]
ADP + [TGF-beta receptor I] phosphate
-
TGF-beta signalling pathway regulation, overview
-
-
?
additional information
?
-
TGF-beta signaling is involved in a wide range of cellular processes and various disease states in humans, R-Smad phosphorylation plays a key role
-
-
?
additional information
?
-
-
TGF-beta signaling is involved in a wide range of cellular processes and various disease states in humans, R-Smad phosphorylation plays a key role
-
-
?
additional information
?
-
the TGF-beta pathway is overactivated in myelodysplastic syndrome, MDS, involving ineffective hematopoiesis leading to peripheral cytopenias. Suppression of the TGF-beta signaling leads to in vitro enhancement of hematopoiesis, overview. TBRi inhibition can improve anemia in a model of bone marrow failure, overview
-
-
?
additional information
?
-
-
activin receptor-like kinase-7, ALK7, induces apoptosis through activation of MAPKs, e.g. SEK1, in a Smad3-dependent mechanism in hepatoma cells
-
-
?
additional information
?
-
-
ALK4 forms a complex with type II serine/threonine transmembrane receptor ActRIIB or ActRII and activin for initiation of signaling, ALK3 forms a complex with bone morphogenetic protein-2
-
-
?
additional information
?
-
-
in TGF-beta signaling, phosphorylated Smad2 and Smad3 form a complex with tumor suppressor Smad4, the complex is translocated to the nucleus, nuclear translocation of Smad2 and Smad3 in absence of Smad4 is not sufficient for TGF-beta-induced transcriptional responses, Smad4 mutations occur in some human cancers and inactivate the TGF-beta signaling, overview
-
-
?
additional information
?
-
-
TGF-beta is responsible for induction of growth arrest in cells via the transforming growth factor-beta receptor I, the inhibition can be blocked by cell treatment with SD-093overview
-
-
?
additional information
?
-
-
the enzyme is involved in p38 MAPK activation
-
-
?
additional information
?
-
-
the TGF-beta receptor kinase is involved in transforming growth in advanced carcinogenesis and in epithelial-to-mesenchymal cell transition, EMT, overview
-
-
?
additional information
?
-
-
the TGF-beta type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta, th TGF-beta type II receptor is required for for TGF-beta binding and signaling induction activity, overview
-
-
?
additional information
?
-
-
ALK5 performs autophosphorylation, substrate specificities of recombinant wild-type and mutant T204D ALK5, ALK5 is the intracellular domain of the transforming growth factor beta type-I receptor
-
-
?
additional information
?
-
ALK1 mutations cause hereditary hemorrhagic telangiectasia in association with pulmonary arterial hypertension, PAH, in patients
-
-
?
additional information
?
-
-
ALK1 mutations cause hereditary hemorrhagic telangiectasia in association with pulmonary arterial hypertension, PAH, in patients
-
-
?
additional information
?
-
-
ALK7 is a receptor for nodal and activin AB and B, overview. The insulin promoter is activated by Smad2, Smad3 and the pancreatic and duodenal homeobox factor-1, PDX-1, in the ALK7 pathway, overview
-
-
?
additional information
?
-
-
cyclin G2 mRNA is strongly up-regulated by Nodal and ALK7, Nodal and ALK7 decrease the expression of Skp1 and Skp2 and increase cyclin G2 levels. The antiproliferative effect of Nodal/ALK7 on ovarian cancer cells is in part mediated by cyclin G2, regulation, overview
-
-
?
additional information
?
-
-
signaling by RON, a phosphotyrosine kinase receptor, cooperates with Smad4-independent TGF-beta signaling to promote cell motility and invasion, knocking down RON expression in Smad4-deficient cells suppresses TGF-beta-mediated motility and invasion. Functional inactivation by site-directed mutations of two Smad binding sites on the RON promoter inhibits TGF-beta-mediated repression of RON promoter activity, cross-talk of Smad4-independent TGF-beta signaling and the RON pathway promotes an invasive phenotype, overview
-
-
?
additional information
?
-
-
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
ATP + [TGF-beta receptor I]
ADP + [TGF-beta receptor I] phosphate
-
-
-
?
ATP + Smad
ADP + phosphorylated Smad
-
involved in ALK5 activation of p38 MAPK signaling and of GADDbeta45 and BGN expression induced by TGF-beta
-
-
?
ATP + [TGF-beta receptor II]
ADP + [TGF-beta receptor II] phosphate
-
regulation and metabolism, overview
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
TGF-beta-induced phosphorylation by TbetaRI receptor kinase at both phosphorylation sites Ser465 and Ser467 leads to release of Smad2 from membrane-anchored protein SARA and signaling co-mediator Smad4, translocation into the nucleus, and regulation of target gene expression
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
step in the MAPK signaling pathway via JNK and p38
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
TGF-beta- or actividin-induced phosphorylation
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
-
TGF-beta-mediated activation of Smad2 by the TGF-beta receptor
-
-
?
ATP + Smad3
ADP + phosphorylated Smad3
-
step in the MAPK signaling pathway via JNK and p38
-
-
?
ATP + Smad3
ADP + phosphorylated Smad3
-
TGF-beta-mediated activation of Smad3 by the TGF-beta receptor
-
-
?
ATP + [actividin receptor]
ADP + [actividin receptor] phosphate
-
activins regulate pancreatic development, differentiation and insulin secretion, insulin gene is a target in activin receptor-like kinase 7 signaling pathway in pancreatic beta-cells, SBE and A/GG elements of the human insulin promoter are involved in the regulation of the ALK7 signal, regulation, overview
-
-
?
ATP + [TGF-beta receptor I]
ADP + [TGF-beta receptor I] phosphate
-
TGF-beta signalling pathway regulation, overview
-
-
?
additional information
?
-
TGF-beta signaling is involved in a wide range of cellular processes and various disease states in humans, R-Smad phosphorylation plays a key role
-
-
?
additional information
?
-
-
TGF-beta signaling is involved in a wide range of cellular processes and various disease states in humans, R-Smad phosphorylation plays a key role
-
-
?
additional information
?
-
the TGF-beta pathway is overactivated in myelodysplastic syndrome, MDS, involving ineffective hematopoiesis leading to peripheral cytopenias. Suppression of the TGF-beta signaling leads to in vitro enhancement of hematopoiesis, overview. TBRi inhibition can improve anemia in a model of bone marrow failure, overview
-
-
?
additional information
?
-
-
activin receptor-like kinase-7, ALK7, induces apoptosis through activation of MAPKs, e.g. SEK1, in a Smad3-dependent mechanism in hepatoma cells
-
-
?
additional information
?
-
-
ALK4 forms a complex with type II serine/threonine transmembrane receptor ActRIIB or ActRII and activin for initiation of signaling, ALK3 forms a complex with bone morphogenetic protein-2
-
-
?
additional information
?
-
-
in TGF-beta signaling, phosphorylated Smad2 and Smad3 form a complex with tumor suppressor Smad4, the complex is translocated to the nucleus, nuclear translocation of Smad2 and Smad3 in absence of Smad4 is not sufficient for TGF-beta-induced transcriptional responses, Smad4 mutations occur in some human cancers and inactivate the TGF-beta signaling, overview
-
-
?
additional information
?
-
-
TGF-beta is responsible for induction of growth arrest in cells via the transforming growth factor-beta receptor I, the inhibition can be blocked by cell treatment with SD-093overview
-
-
?
additional information
?
-
-
the enzyme is involved in p38 MAPK activation
-
-
?
additional information
?
-
-
the TGF-beta receptor kinase is involved in transforming growth in advanced carcinogenesis and in epithelial-to-mesenchymal cell transition, EMT, overview
-
-
?
additional information
?
-
-
the TGF-beta type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta, th TGF-beta type II receptor is required for for TGF-beta binding and signaling induction activity, overview
-
-
?
additional information
?
-
ALK1 mutations cause hereditary hemorrhagic telangiectasia in association with pulmonary arterial hypertension, PAH, in patients
-
-
?
additional information
?
-
-
ALK1 mutations cause hereditary hemorrhagic telangiectasia in association with pulmonary arterial hypertension, PAH, in patients
-
-
?
additional information
?
-
-
ALK7 is a receptor for nodal and activin AB and B, overview. The insulin promoter is activated by Smad2, Smad3 and the pancreatic and duodenal homeobox factor-1, PDX-1, in the ALK7 pathway, overview
-
-
?
additional information
?
-
-
cyclin G2 mRNA is strongly up-regulated by Nodal and ALK7, Nodal and ALK7 decrease the expression of Skp1 and Skp2 and increase cyclin G2 levels. The antiproliferative effect of Nodal/ALK7 on ovarian cancer cells is in part mediated by cyclin G2, regulation, overview
-
-
?
additional information
?
-
-
signaling by RON, a phosphotyrosine kinase receptor, cooperates with Smad4-independent TGF-beta signaling to promote cell motility and invasion, knocking down RON expression in Smad4-deficient cells suppresses TGF-beta-mediated motility and invasion. Functional inactivation by site-directed mutations of two Smad binding sites on the RON promoter inhibits TGF-beta-mediated repression of RON promoter activity, cross-talk of Smad4-independent TGF-beta signaling and the RON pathway promotes an invasive phenotype, overview
-
-
?
additional information
?
-
-
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Mg2+
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1'R,5'S,6'S)-2-(3',5'-dibromo-1',6'-dihydroxy-4'-oxocyclohex-2'-enyl) acetonitrile
the small dibromotyrosine derivative purified from Pseudoceratina sp. suppresses TGF-beta responsiveness by inhibiting TGF-beta type I receptor serine/threonine kinase activity. The compound inhibits the TGF-beta-stimulated transcriptional activations of 3TP-Lux and decreases phosphorylated Smad2/3 levels and the nuclear translocation of Smad2/3 increased by TGF-beta. The compound inhibits TGF-beta-induced EMT and wound healing of A-549 cells and is a potential therapeutic agent for fibrotic disease and cancer treatment. The compound has no effects on TGF-beta receptor synthesis but attenuates TGF-beta-induced transcriptional activation in Mv1Lu cells and TGF-beta-induced expression of fibronectin and PAI-1 in A549 and NMuMG cells and TGF-beta-induced cell migration
LY-2157299
LY-2157299 inhibits TGF-beta mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. In vivo administration of LY-2157299 ameliorates anemia in a TGF-beta overexpressing transgenic mouse model of bone marrow failure. Treatment with LY-2157199 stimulates hematopoiesis from primary myelodysplastic syndrome bone marrow specimens
SD-208
inhibition of the TBRI kinase inhibits TGF-beta-mediated smad2 activation in hematopoietic progenitors, alleviates anemia, and stimulates hematopoiesis in vivo in bone marrow
4(quinolin-4-yl)-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
-
IC50 of 0.00005-0.0013 mM
4-phenyl substituted pyrazole inhibitors
-
inhibitory potency of 4-phenyl substituted pyrazole derivatives, IC50 of 30-555 nM, overview
-
4-phenyl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
-
IC50 of 0.000005-0.0195 mM
LY2109761
-
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells, it LY2109761 enhanced apoptosis only in the presence of exogenously added TGF-beta1
LY2157299
-
inhibits Smad3 and Smad3 phosphorylation and antagonizes TGF-beta receptor I kinase activity in vivo in human cancer cells implanted into nude mice, pharmacokinetic model, overview
LY566578
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 70 nM, mechanism
LY580276
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 580 nM, mechanism
PEG10
-
ancient retroviral/retrotransposon element intergrated as a single copy gene in to human chromosome 7q21, encodes two splicing varaiants PEG10-RF1 and PEG10-RF1/2, gag- and gag-pol-like proteins that interact with TGF-beta family proteins, DNA and amino acid sequence deteramination and analysis of PEG10-RF1, PEG10-RF1 inhibits ALK1 and ALK5 signaling by direct interaction, overview
SB-431542
-
specific TGF-beta receptor kinase inhibitor, a potent antitumor agent for human cancers, induces anchorage-independent cell growth in TGF-beta growth-inhibited cells, and colony formation in growth-induced cells, overview
LY364947
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 175 nM, mechanism
additional information
-
a dominant negative SEK1 mutant abolishes the ALK7-induced apoptosis
-
additional information
-
LY294002 completely abolishes the ALK7 mutant T194D/Smad3-induced synergistic effect by inhibiting interaction between the Smad3-Linker and PDX-1
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
SARA protein
i.e. Smad anchor for receptor activation protein, binding site for co-modulator Smad4, modulates self-association of partially phosphorylated Smad2 preventing premature release of monophosphorylated substrate, interaction with Smad2 via the Smad2 MH2 domain
-
TGF-beta
binds to and activates TbetaRI receptor kinase that phosphorylates Smad2
-
actividin A
-
required for activity in a complex formed with ALK4 and ActRIIB or ActRII, identification of the functional binding site
-
actividin B
-
required for activity in a complex formed with ALK4 and ActRIIB or ActRII, identification of the functional binding site
-
actividin
TGF-beta receptor I and ALK7 possess an actividin receptor-binding domain
-
TGF-beta
-
activates the TGF-beta type I receptor kinase by binding, affects BGN and GADDbeta45 expression in PANC-1 and M-63 cells via ALK5 and Smad phosphorylation/activation, overview
-
TGF-beta
-
binds and activates the TGF-beta receptor kinase, promotes transforming growth in advanced carcinogenesis, influences transcription activity of cells
-
TGF-beta
-
i.e. transforming growth factor-beta, interacts with and activates type I transforming growth factor-beta receptor
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
[Study on the correlation of transforming growth factor beta1 and its receptors with spontaneous abortion after in vitro fertilization and embryo transfer]
Abruptio Placentae
BMPR2 is required for postimplantation uterine function and pregnancy maintenance.
Abscess
Expression of various TGF-beta isoforms and type I receptor in necrotizing human brain lesions.
Acidosis
Disruption of auto-inhibition underlies conformational signaling of ASIC1a to induce neuronal necroptosis.
Acrospiroma
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
ACTH-Secreting Pituitary Adenoma
Bone morphogenetic protein 4 and bone morphogenetic protein receptor expression in the pituitary gland of adult dogs in healthy condition and with ACTH-secreting pituitary adenoma.
Acute Kidney Injury
Necroptosis in 3-chloro-1, 2-propanediol (3-MCPD)-dipalmitate-induced acute kidney injury in vivo and its repression by miR-223-3p.
Acute Kidney Injury
Novel Roles of Necroptosis Mediator Receptor-Interacting Protein Kinase 3 in Kidney Injury.
Acute Kidney Injury
RIPK3 mediates renal tubular epithelial cell apoptosis in endotoxin?induced acute kidney injury.
Acute Kidney Injury
RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction.
Acute Kidney Injury
The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Acute Lung Injury
RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury.
Adenocarcinoma
Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.
Adenocarcinoma
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.
Adenocarcinoma
Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Adenocarcinoma
Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Adenocarcinoma
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
Adenocarcinoma
Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis.
Adenocarcinoma
Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.
Adenocarcinoma
Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma.
Adenocarcinoma
Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage.
Adenocarcinoma
Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection.
Adenocarcinoma
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Adenocarcinoma
Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study.
Adenocarcinoma
The role of Sp1 in the differential expression of transforming growth factor-beta receptor type II in human breast adenocarcinoma MCF-7 cells.
Adenocarcinoma
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
Adenocarcinoma of Lung
Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
Adenocarcinoma of Lung
lncCRLA enhanced chemoresistance in lung adenocarcinoma that underwent epithelial-mesenchymal transition.
Adenocarcinoma of Lung
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
Adenocarcinoma of Lung
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Adenocarcinoma of Lung
Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection.
Adenocarcinoma of Lung
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells.
Adenocarcinoma, Bronchiolo-Alveolar
Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.
Adenocarcinoma, Bronchiolo-Alveolar
[Distribution of transforming growth factor-beta and its receptor in bronchiolo-alveolar cell hyperplasia and bronchiolo-alveolar carcinoma]
Adenoma
Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption.
Adenoma
Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development.
Adenoma
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Adenoma
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Adenoma
Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells.
Adenoma
Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
Adenoma
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Adenoma
Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.
Adenoma
The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer.
Adenoma
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Adenoma
Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors.
Adenoma
[Changes in gene expression during the proliferative processes of parathyroid gland]
Adrenocortical Carcinoma
Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Alzheimer Disease
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Alzheimer Disease
Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.
Alzheimer Disease
Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.
Alzheimer Disease
RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.
Alzheimer Disease
RIPK1 promotes inflammation and ?-amyloid accumulation in Alzheimer's disease.
Alzheimer Disease
The Expression of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) in Hippocampal Arterioles Declines During Progression of Alzheimer's Disease.
Ameloblastoma
Immunoexpression of BMP-2 and BMP-4 and their receptors, BMPR-IA and BMPR-II, in ameloblastomas and adenomatoid odontogenic tumors.
Amyotrophic Lateral Sclerosis
Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Anemia
Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.
Anemia
Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation.
Anemia
Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression.
Aneurysm
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Aneurysm
Prevalence of and Factors Associated with Arterial Aneurysms in Patients with Hereditary Hemorrhagic Telangiectasia: 17-year Retrospective Series of 418 Patients.
Aneurysm
Transforming Growth Factor-beta Signaling in Thoracic Aortic Aneurysm Development: A Paradox in Pathogenesis.
Aneurysm, Dissecting
Transforming growth factor-beta receptor type II mutation in a patient with bicuspid aortic valve disease and intraoperative aortic dissection.
Aneurysm, Dissecting
[Familial aortic dissection of non-Marfan syndrome with mutations in the transforming growth factor-beta receptor type 1 genes].
Angiodysplasia
Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Angiodysplasia
DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population.
Angiodysplasia
[Analysis of molecular background of hereditary haemorrhagic telangiectasia--Rendu-Osler-Weber disease--preliminary results]
Anovulation
Alteration of TGFB1, GDF9, and BMPR2 gene expression in preantral follicles of an estradiol valerate-induced polycystic ovary mouse model can lead to anovulation, polycystic morphology, obesity, and absence of hyperandrogenism.
Aortic Aneurysm
[Marfan-like aortic aneurysm syndrome; A surgical experience with Loeys-Dietz syndrome]
Aortic Aneurysm, Abdominal
Association of the TGF-beta receptor genes with abdominal aortic aneurysm.
Aortic Aneurysm, Thoracic
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Aortic Aneurysm, Thoracic
Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections.
Aortic Aneurysm, Thoracic
Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity.
Aortic Valve Disease
AGEs-RAGE axis causes endothelial-to-mesenchymal transition in early calcific aortic valve disease via TGF-?1 and BMPR2 signaling.
Arteriovenous Malformations
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Arteriovenous Malformations
Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia.
Arteriovenous Malformations
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Arteriovenous Malformations
Association of ACVRL1 genetic polymorphisms with arteriovenous malformations: A case-control study and meta-analysis.
Arteriovenous Malformations
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
Arteriovenous Malformations
Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia.
Arteriovenous Malformations
Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.
Arteriovenous Malformations
Context-specific interactions between Notch and ALK1 cannot explain ALK1-associated arteriovenous malformations.
Arteriovenous Malformations
Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia.
Arteriovenous Malformations
Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia.
Arteriovenous Malformations
Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.
Arteriovenous Malformations
De novo cerebrovascular malformation in the adult mouse after endothelial Alk1 deletion and angiogenic stimulation.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arteriovenous Malformations
Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients.
Arteriovenous Malformations
Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia.
Arteriovenous Malformations
Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression.
Arteriovenous Malformations
Familial occurrence of brain arteriovenous malformation: a novel ACVRL1 mutation detected by whole exome sequencing.
Arteriovenous Malformations
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Arteriovenous Malformations
Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.
Arteriovenous Malformations
Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin.
Arteriovenous Malformations
Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.
Arteriovenous Malformations
Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).
Arteriovenous Malformations
Matrix Gla protein deficiency causes arteriovenous malformations in mice.
Arteriovenous Malformations
Mutation analysis in hereditary haemorrhagic telangiectasia in Germany reveals 11 novel ENG and 12 novel ACVRL1/ALK1 mutations.
Arteriovenous Malformations
Mutation analysis of "Endoglin" and "Activin receptor-like kinase" genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique.
Arteriovenous Malformations
Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models Of Hereditary Hemorrhagic Telangiectasia.
Arteriovenous Malformations
Prevalence of and Factors Associated with Arterial Aneurysms in Patients with Hereditary Hemorrhagic Telangiectasia: 17-year Retrospective Series of 418 Patients.
Arteriovenous Malformations
Pulmonary Hypertension in Hereditary Haemorrhagic Teleangiectasia.
Arteriovenous Malformations
Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease).
Arteriovenous Malformations
Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.
Arteriovenous Malformations
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
Arteriovenous Malformations
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Arteriovenous Malformations
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
Arteriovenous Malformations
[Genetic diagnostics of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)].
Arthritis
A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain.
Arthritis
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.
Arthritis
Primary immunodeficiency with chronic enteropathy and developmental delay in a boy arising from a novel homozygous RIPK1 variant.
Arthritis
RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis.
Arthritis
RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL.
Arthritis
TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody.
Arthritis
The caspase-8/RIPK3 signaling axis in antigen presenting cells controls the inflammatory arthritic response.
Arthritis
The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts.
Arthritis, Experimental
Interferon-gamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritis.
Arthritis, Experimental
Modulation of TNFR 1-triggered two opposing signals for inflammation and apoptosis via RIPK 1 disruption by geldanamycin in rheumatoid arthritis.
Arthritis, Rheumatoid
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Arthritis, Rheumatoid
Up-regulated microRNA-411 or declined RIPK1 inhibits proliferation and promotes apoptosis of synoviocytes in rheumatoid arthritis mice via decreased NF-?B pathway.
Asthma
Airway epithelial cell necroptosis contributes to asthma exacerbation in a mouse model of house dust mite-induced allergic inflammation.
Asthma
Association between Genetic Variations of Transforming Growth Factor Beta Receptor Type III and Asthma in a Korean Population.
Asthma
Gene-gene interaction in regulatory T-cell function in atopy and asthma development in childhood.
Asthma
In vitro wounding of airway smooth muscle cell monolayers increases expression of TGF-beta receptors.
Asthma
LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.
Atherosclerosis
ALK5 deficiency inhibits macrophage inflammation and lipid loading by targeting KLF4.
Atherosclerosis
Anti-inflammatory and anti-atherogenic role of BMP receptor II in atherosclerosis.
Atherosclerosis
Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells.
Atherosclerosis
Cell-specific and athero-protective roles for RIPK3 in a murine model of atherosclerosis.
Atherosclerosis
Genomic locus proteomic screening identifies the NF-?B signaling pathway components NF?B1 and IKBKG as transcriptional regulators of Ripk3 in endothelial cells.
Atherosclerosis
Impact of myeloid RIPK1 gene deletion on atherogenesis in ApoE-deficient mice.
Atherosclerosis
Increased type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge.
Atherosclerosis
Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis.
Atherosclerosis
RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-?B Activation and Atherogenesis in Mice.
Atherosclerosis
The core-aldehyde 9-oxononanoyl cholesterol increases the level of transforming growth factor beta1-specific receptors on promonocytic U937 cell membranes.
Autoimmune Diseases
The latest information on the RIPK1 post-translational modifications and functions.
Autoimmune Diseases
The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.
Autoimmune Lymphoproliferative Syndrome
Caspase-8 deficiency in mouse embryos triggers chronic RIPK1-dependent activation of inflammatory genes, independently of RIPK3.
Autoimmune Lymphoproliferative Syndrome
Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis.
Bacterial Infections
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
Bacterial Infections
Kinase Activities of RIPK1 and RIPK3 Can Direct IFN-? Synthesis Induced by Lipopolysaccharide.
Bacterial Infections
RIPK3 in cell death and inflammation: the good, the bad, and the ugly.
Bicuspid Aortic Valve Disease
Transforming growth factor-beta receptor type II mutation in a patient with bicuspid aortic valve disease and intraoperative aortic dissection.
Blister
Expression of TGF-beta receptor 1 and Smads in the tissues of primary spontaneous pneumothorax.
Bone Marrow Failure Disorders
Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.
Bone Resorption
Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
Bone Resorption
Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-?B and MAPKs signaling pathways.
Bone Resorption
Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1- I?B-NF-?B Pathway.
Bone Resorption
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.
Bowen's Disease
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Brain Edema
Cell-specific activation of RIPK1 and MLKL after intracerebral hemorrhage in mice.
Brain Edema
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Brain Injuries
Caspofungin Suppresses Brain Cell Necroptosis in Ischemic Stroke Rats via Up-Regulation of Pellino3.
Brain Injuries
Inhibiting of RIPK3 attenuates early brain injury following subarachnoid hemorrhage: Possibly through alleviating necroptosis.
Brain Injuries
Protective effect of mild-induced hypothermia against moderate traumatic brain injury in rats involved in necroptotic and apoptotic pathways.
Brain Injuries
The possible roles of necroptosis during cerebral ischemia and ischemia / reperfusion injury.
Brain Injuries, Traumatic
Functional suppression of Ripk1 blocks the NF-?B signaling pathway and induces neuron autophagy after traumatic brain injury.
Brain Injuries, Traumatic
Protective effect of mild-induced hypothermia against moderate traumatic brain injury in rats involved in necroptotic and apoptotic pathways.
Brain Injuries, Traumatic
RIPK1 or RIPK3 deletion prevents progressive neuronal cell death and improves memory function after traumatic brain injury.
Brain Ischemia
Necrostatin-1 Improves Long-term Functional Recovery Through Protecting Oligodendrocyte Precursor Cells After Transient Focal Cerebral Ischemia in Mice.
Brain Ischemia
The possible roles of necroptosis during cerebral ischemia and ischemia / reperfusion injury.
Brain Neoplasms
A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Brain Neoplasms
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
Breast Neoplasms
A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells.
Breast Neoplasms
ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells.
Breast Neoplasms
An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Breast Neoplasms
Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features.
Breast Neoplasms
Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells.
Breast Neoplasms
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
Breast Neoplasms
Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3.
Breast Neoplasms
Control of type II transforming growth factor-beta receptor expression by integrin ligation.
Breast Neoplasms
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Breast Neoplasms
Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
Breast Neoplasms
Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
Breast Neoplasms
Differential involvement of TAK1, RIPK1 and NF-?B signaling in Smac mimetic-induced cell death in breast cancer cells.
Breast Neoplasms
Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.
Breast Neoplasms
Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer.
Breast Neoplasms
EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Breast Neoplasms
Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Breast Neoplasms
Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens.
Breast Neoplasms
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Breast Neoplasms
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Breast Neoplasms
Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.
Breast Neoplasms
HER-2/neu-Positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications.
Breast Neoplasms
Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
Breast Neoplasms
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Breast Neoplasms
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
Breast Neoplasms
Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer.
Breast Neoplasms
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Breast Neoplasms
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Breast Neoplasms
Nodal and activin receptor-like kinase 7 induce apoptosis in human breast cancer cell lines: Role of caspase 3.
Breast Neoplasms
Overexpression of Activin Receptor-like Kinase 7 in Breast Cancer Cells Is Associated with Decreased Cell Growth and Adhesion.
Breast Neoplasms
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
Breast Neoplasms
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Breast Neoplasms
Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients.
Breast Neoplasms
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Breast Neoplasms
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Breast Neoplasms
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis.
Breast Neoplasms
RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence.
Breast Neoplasms
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
Breast Neoplasms
TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.
Breast Neoplasms
TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.
Breast Neoplasms
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Breast Neoplasms
TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.
Breast Neoplasms
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
Breast Neoplasms
The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling.
Breast Neoplasms
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
Breast Neoplasms
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
Breast Neoplasms
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Breast Neoplasms
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
Breast Neoplasms
Transcriptional up-regulation of BMP-4 and BMPR-II genes in the peripheral blood of breast cancer patients: A pilot study.
Breast Neoplasms
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Breast Neoplasms
Transforming growth factor-?-induced lncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC(A) cells.
Breast Neoplasms
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.
Breast Neoplasms
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.
Breast Neoplasms
Transforming growth factor-beta1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells.
Bronchitis
Fine particulate matter (PM2.5) enhances airway hyperresponsiveness (AHR) by inducing necroptosis in BALB/c mice.
Burkitt Lymphoma
Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells.
Carcinogenesis
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
Carcinogenesis
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Carcinogenesis
ALK7 Promotes Vascular Smooth Muscle Cells Phenotypic Modulation by Negative Regulating PPAR? Expression.
Carcinogenesis
Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Carcinogenesis
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
Carcinogenesis
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
Carcinogenesis
BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells.
Carcinogenesis
Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.
Carcinogenesis
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Carcinogenesis
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Carcinogenesis
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Carcinogenesis
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Carcinogenesis
Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.
Carcinogenesis
Epithelial HMGB1 Delays Skin Wound Healing and Drives Tumor Initiation by Priming Neutrophils for NET Formation.
Carcinogenesis
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Carcinogenesis
Expression of endoglin and the activin receptor-like kinase 1 in skin suggests a role for these receptors in normal skin function and skin tumorigenesis.
Carcinogenesis
Expression of TGF-beta type II receptor antisense RNA impairs TGF-beta signaling in vitro and promotes mammary gland differentiation in vivo.
Carcinogenesis
Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane.
Carcinogenesis
Finding a new role for NEMO: A key player in preventing hepatocyte apoptosis and liver tumorigenesis by inhibiting RIPK1.
Carcinogenesis
Genetic alterations in the transforming growth factor receptor complex in sporadic endometrial carcinoma.
Carcinogenesis
Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.
Carcinogenesis
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
Carcinogenesis
Lack of expression of transforming growth factor-beta type II receptor associated with malignant progression in human salivary gland cell clones.
Carcinogenesis
Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.
Carcinogenesis
Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer.
Carcinogenesis
RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.
Carcinogenesis
RIPK1 binds MCU to mediate induction of mitochondrial Ca2+ uptake and promote colorectal oncogenesis.
Carcinogenesis
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
Carcinogenesis
RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis.
Carcinogenesis
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Carcinogenesis
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Carcinogenesis
Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer.
Carcinogenesis
Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Carcinogenesis
Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-beta receptor expression and altered responses to these growth factors.
Carcinoma
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Carcinoma
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Carcinoma
A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.
Carcinoma
An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Carcinoma
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
Carcinoma
Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination.
Carcinoma
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
Carcinoma
Breast Cancer Special Feature: Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.
Carcinoma
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Carcinoma
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Carcinoma
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Carcinoma
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Carcinoma
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Carcinoma
Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.
Carcinoma
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Carcinoma
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Carcinoma
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Carcinoma
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Carcinoma
Expression of TGF-alpha/EGF and TGF-beta receptors in human colon carcinoma cell lines.
Carcinoma
Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
Carcinoma
Frequent aberration of the transforming growth factor-beta receptor II gene in cell lines but no apparent mutation in pre-invasive and invasive carcinomas of the uterine cervix.
Carcinoma
Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells.
Carcinoma
Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells.
Carcinoma
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Carcinoma
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
Carcinoma
Identification of genetic alterations in the TGFbeta type II receptor gene promoter.
Carcinoma
Immunoexpression of bone morphogenetic protein-2 (BMP-2), BMP receptor type IA, and BMP receptor type II in metastatic and non-metastatic lower lip squamous cell carcinoma.
Carcinoma
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Carcinoma
Inhibition of TGF-beta1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases.
Carcinoma
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Carcinoma
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Carcinoma
Lack of transforming growth factor-? signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
Carcinoma
Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Carcinoma
Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.
Carcinoma
Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway.
Carcinoma
Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
Carcinoma
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Carcinoma
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.
Carcinoma
Monocyte chemoattractant protein-1 is generated via TGF-beta by myofibroblasts in gastric intestinal metaplasia and carcinoma without H. pylori infection.
Carcinoma
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Carcinoma
Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
Carcinoma
Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma.
Carcinoma
Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
Carcinoma
Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells.
Carcinoma
Phospho-?Np63?-responsive microRNAs contribute to the regulation of necroptosis in squamous cell carcinoma upon cisplatin exposure.
Carcinoma
Reduced levels of transforming growth factor-beta type I receptor in human gastric carcinomas.
Carcinoma
Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability.
Carcinoma
RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway.
Carcinoma
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Carcinoma
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma.
Carcinoma
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Carcinoma
TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Carcinoma
TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
Carcinoma
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Carcinoma
Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Carcinoma
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Carcinoma
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Carcinoma
Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1.
Carcinoma
Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition.
Carcinoma
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Carcinoma
Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas.
Carcinoma
Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors.
Carcinoma
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Carcinoma
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Carcinoma
[Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer.]
Carcinoma
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Carcinoma, Basal Cell
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Carcinoma, Ductal
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Embryonal
Activation of the murine type II transforming growth factor-beta receptor gene: up-regulation and function of the transcription factor Elf-3/Ert/Esx/Ese-1.
Carcinoma, Embryonal
Transcriptional activation of the type II transforming growth factor-beta receptor gene upon differentiation of embryonal carcinoma cells.
Carcinoma, Embryonal
Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene.
Carcinoma, Hepatocellular
A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.
Carcinoma, Hepatocellular
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Carcinoma, Hepatocellular
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells.
Carcinoma, Hepatocellular
Biology of transforming growth factor beta in hepatocarcinogenesis.
Carcinoma, Hepatocellular
Expression and genetic polymorphism of necroptosis related protein RIPK1 is correlated with severe hepatic ischemia-reperfusion injury and prognosis after hepatectomy in hepatocellular carcinoma patients.
Carcinoma, Hepatocellular
Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
Carcinoma, Hepatocellular
Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K.
Carcinoma, Hepatocellular
Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
Carcinoma, Hepatocellular
Increased type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge.
Carcinoma, Hepatocellular
Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma.
Carcinoma, Hepatocellular
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.
Carcinoma, Hepatocellular
Loss of endogenous TGF-beta effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF.
Carcinoma, Hepatocellular
Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells.
Carcinoma, Hepatocellular
Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein.
Carcinoma, Hepatocellular
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.
Carcinoma, Hepatocellular
OTULIN Prevents Liver Inflammation and Hepatocellular Carcinoma by Inhibiting FADD- and RIPK1 Kinase-Mediated Hepatocyte Apoptosis.
Carcinoma, Hepatocellular
Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis.
Carcinoma, Hepatocellular
Relation of type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma.
Carcinoma, Hepatocellular
RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
Carcinoma, Hepatocellular
Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Carcinoma, Non-Small-Cell Lung
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Carcinoma, Non-Small-Cell Lung
Prognostic Significance of CHIP and RIPK3 in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
Carcinoma, Ovarian Epithelial
Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines.
Carcinoma, Ovarian Epithelial
Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
Carcinoma, Ovarian Epithelial
MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
Carcinoma, Ovarian Epithelial
Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7.
Carcinoma, Renal Cell
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.
Carcinoma, Renal Cell
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Carcinoma, Renal Cell
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.
Carcinoma, Renal Cell
The type III TGF-{beta} receptor regulates epithelial and cancer cell migration through {beta}-arrestin2-mediated activation of Cdc42.
Carcinoma, Renal Cell
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Carcinoma, Squamous Cell
A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression.
Carcinoma, Squamous Cell
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Carcinoma, Squamous Cell
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Carcinoma, Squamous Cell
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Carcinoma, Squamous Cell
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Carcinoma, Squamous Cell
Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Identification of genetic alterations in the TGFbeta type II receptor gene promoter.
Carcinoma, Squamous Cell
Immunoexpression of bone morphogenetic protein-2 (BMP-2), BMP receptor type IA, and BMP receptor type II in metastatic and non-metastatic lower lip squamous cell carcinoma.
Carcinoma, Squamous Cell
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Carcinoma, Squamous Cell
Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
Carcinoma, Squamous Cell
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Phospho-?Np63?-responsive microRNAs contribute to the regulation of necroptosis in squamous cell carcinoma upon cisplatin exposure.
Carcinoma, Squamous Cell
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Carcinoma, Squamous Cell
TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Cardiomegaly
BMP TYPE I RECEPTOR ALK2 IS REQUIRED FOR ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY.
Cardiomegaly
Critical role of X-box binding protein 1 in NADPH oxidase 4-triggered cardiac hypertrophy is mediated by receptor interacting protein kinase 1.
Cardiomyopathy, Dilated
A new discovered gene mutation in a child with dilated cardiomyopathy.
Cardiovascular Diseases
ALK7 Promotes Vascular Smooth Muscle Cells Phenotypic Modulation by Negative Regulating PPAR? Expression.
Cardiovascular Diseases
Generation of a floxed allele of the mouse BMP type II receptor gene.
Cardiovascular Diseases
Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice.
Cardiovascular Diseases
Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms.
Cardiovascular Diseases
Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats.
Cardiovascular Diseases
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
caspase-8 deficiency
Caspase-8 deficiency in mouse embryos triggers chronic RIPK1-dependent activation of inflammatory genes, independently of RIPK3.
caspase-8 deficiency
Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis.
caspase-8 deficiency
RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis.
Castleman Disease
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Cataract
Immunolocalization of TGF-beta1, -beta2, and -beta3, and TGF-beta receptors in human lens capsules with lens implants.
Cerebral Hemorrhage
Cell-specific activation of RIPK1 and MLKL after intracerebral hemorrhage in mice.
Cerebral Hemorrhage
Genetic Inhibition of Receptor Interacting Protein Kinase-1 Reduces Cell Death and Improves Functional Outcome After Intracerebral Hemorrhage in Mice.
Cerebral Hemorrhage
Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke.
Cerebrovascular Disorders
Role of activin receptor-like kinase 1 in vascular development and cerebrovascular diseases.
Chlamydophila Infections
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
Cholangiocarcinoma
In situ detection of TGF betas, TGF beta receptor II mRNA and telomerase activity in rat cholangiocarcinogenesis.
Cholangiocarcinoma
[Expression of Smad4 and transforming growth factor-beta1, transforming growth factor-beta receptor II in cholangiocarcinoma tissue and its biological siginificance]
Cholangitis
B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.
Cholangitis
Beta-glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis.
Cholangitis
Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
Cholestasis
Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury.
Cholestasis
I?B kinase?/? control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1.
Chondrosarcoma
BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells.
Chondrosarcoma
BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma.
Chondrosarcoma
Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
Choriocarcinoma
Endoglin, a component of the TGF-beta receptor system, is a differentiation marker of human choriocarcinoma cells.
Choriocarcinoma
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Choroidal Neovascularization
Expression of transforming growth factor-beta receptors in normal rat retina and experimental choroidal neovascularization.
Chronic Periodontitis
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Cleft Lip
Transforming growth factor-beta receptor type 1 (TGFBR1) is not associated with non-syndromic cleft lip with or without cleft palate in patients of Central European descent.
Cleft Palate
All-trans retinoic acid inhibited chondrogenesis of mouse embryonic palate mesenchymal cells by down-regulation of TGF-beta/Smad signaling.
Cleft Palate
Transforming growth factor-beta receptor type 1 (TGFBR1) is not associated with non-syndromic cleft lip with or without cleft palate in patients of Central European descent.
Cleft Palate
[The preliminary study on transforming growth factor-beta 3, activin receptor-like kinase 5 expression in 2, 3, 7, 8-tetrachloro-p-dibenzodioxin and dexamethasone induced palatal cleft in mice]
Colitis
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Colitis
A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis.
Colitis
B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.
Colitis
Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer.
Colitis
Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients.
Colitis
Necroptosis is dispensable for the development of inflammation-associated or sporadic colon cancer in mice.
Colitis
NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-?B-Dependent and -Independent Functions.
Colitis
RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-immuno crosstalk.
Colitis
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Colitis
The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis.
Colitis
The scaffold-dependent function of RIPK1 in dendritic cells promotes injury-induced colitis.
Colitis
Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
Colitis, Ulcerative
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
Colitis, Ulcerative
Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients.
Colonic Neoplasms
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Colonic Neoplasms
Adenosine induces apoptosis through TNFR1/RIPK1/P38 axis in colon cancer cells.
Colonic Neoplasms
Cationic peroxidase from proso millet induces human colon cancer cell necroptosis by regulating autocrine TNF-? and RIPK3 demethylation.
Colonic Neoplasms
Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.
Colonic Neoplasms
Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
Colonic Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Colonic Neoplasms
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.
Colonic Neoplasms
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Colonic Neoplasms
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.
Colonic Neoplasms
Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population.
Colonic Neoplasms
Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
Colonic Neoplasms
Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.
Colonic Neoplasms
RIPK1 binds MCU to mediate induction of mitochondrial Ca2+ uptake and promote colorectal oncogenesis.
Colonic Neoplasms
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
Colonic Neoplasms
RUNX3 inhibits cell proliferation and induces apoptosis by TGF-beta-dependent and -independent mechanisms in human colon carcinoma cells.
Colonic Neoplasms
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Colonic Neoplasms
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
Colonic Neoplasms
The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis.
Colonic Neoplasms
Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype.
Colonic Neoplasms
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Colonic Neoplasms
Uncommon TGFBRI allele is not associated with increased susceptibility to colon cancer.
Colorectal Neoplasms
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
Colorectal Neoplasms
Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer.
Colorectal Neoplasms
CircFAM120B Blocks the Development of Colorectal Cancer by Activating TGF-Beta Receptor II Expression via Targeting miR-645.
Colorectal Neoplasms
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Colorectal Neoplasms
Expression of transforming growth factor beta receptors in normal human colon and sporadic adenocarcinomas.
Colorectal Neoplasms
Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells.
Colorectal Neoplasms
Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
Colorectal Neoplasms
Induction of the expression of genes encoding TGF-beta isoforms and their receptors by inositol hexaphosphate in human colon cancer cells.
Colorectal Neoplasms
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Colorectal Neoplasms
RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection.
Colorectal Neoplasms
RIPK1 binds MCU to mediate induction of mitochondrial Ca2+ uptake and promote colorectal oncogenesis.
Colorectal Neoplasms
RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
Colorectal Neoplasms
Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability.
Colorectal Neoplasms
TGF-beta signaling alterations and susceptibility to colorectal cancer.
Colorectal Neoplasms
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
Colorectal Neoplasms
TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Colorectal Neoplasms
The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis.
Colorectal Neoplasms
The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study.
Colorectal Neoplasms
The mannose 6-phosphate/insulin-like growth factor-II receptor is a substrate of type V transforming growth factor-beta receptor.
Colorectal Neoplasms
The type II transforming growth factor-beta receptor as a tumor-suppressor gene.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic ?-catenin degradation.
Connective Tissue Diseases
High prevalence of vertebral artery tortuosity of Loeys-Dietz syndrome in comparison with Marfan syndrome.
Connective Tissue Diseases
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Connective Tissue Diseases
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Connective Tissue Diseases
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Connective Tissue Diseases
Small platelet microparticle levels are increased in pulmonary arterial hypertension.
Contracture
Controlled release of transforming growth factor-beta receptor kinase inhibitor from thermosensitive Chitosan-based hydrogel: application for prevention of capsular contracture.
Coronary Artery Disease
RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-?B Activation and Atherogenesis in Mice.
Coronary Artery Disease
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Craniosynostoses
Augmentation of Smad-dependent BMP signaling in neural crest cells causes craniosynostosis in mice.
Craniosynostoses
Toward an understanding of nonsyndromic craniosynostosis: altered patterns of TGF-beta receptor and FGF receptor expression induced by intrauterine head constraint.
CREST Syndrome
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Crohn Disease
Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease.
Cysts
A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the pkd2-/- phenotype.
Cysts
Enhanced resistance to soybean cyst nematode Heterodera glycines in transgenic soybean by silencing putative CLE receptors.
Cysts
JNK signaling prevents biliary cyst formation through a CASPASE-8-dependent function of RIPK1 during aging.
Cysts
Synergistic Interaction of CLAVATA1, CLAVATA2, and RECEPTOR-LIKE PROTEIN KINASE 2 in Cyst Nematode Parasitism of Arabidopsis.
Dehydration
Identification of a receptor-like protein kinase gene rapidly induced by abscisic acid, dehydration, high salt, and cold treatments in Arabidopsis thaliana.
Demyelinating Diseases
Cornel Iridoid Glycoside Ameliorated Alzheimer's Disease-Like Pathologies and Necroptosis through RIPK1/MLKL Pathway in Young and Aged SAMP8 Mice.
Demyelinating Diseases
Modulation of vigabatrin induced cerebellar injury: the role of caspase-3 and RIPK1/RIPK3-regulated cell death pathways.
Dermatitis
LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L.
Diabetes Complications
Knockdown of ALK7 inhibits high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells.
Diabetes Mellitus
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Diabetes Mellitus
Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.
Diabetes Mellitus
RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy.
Diabetes Mellitus
Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats.
Diabetes Mellitus, Type 2
DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.
Diabetes Mellitus, Type 2
Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression.
Diabetes Mellitus, Type 2
Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats.
Diabetes Mellitus, Type 2
When Beauty Is Skin Deep: Regulation of the Wound Response by Caspase-8, RIPK3, and the Inflammasome.
Diabetic Cardiomyopathies
Knockdown of ALK7 inhibits high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells.
Diabetic Foot
Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers.
Diabetic Nephropathies
RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy.
Diabetic Nephropathies
Transcription factor 7-like 2 (TCF7L2) regulates activin receptor-like kinase 1 (ALK1)/Smad1 pathway for development of diabetic nephropathy.
Diffuse Intrinsic Pontine Glioma
Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.
Dyspnea
Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise.
Encephalitis
RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.
Endometrial Neoplasms
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Endometrial Neoplasms
Activin A inhibits growth-inhibitory signals by TGF-beta1 in differentiated human endometrial adenocarcinoma cells.
Endometrial Neoplasms
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Endometrial Neoplasms
Genetic alterations in the transforming growth factor receptor complex in sporadic endometrial carcinoma.
Endometrial Neoplasms
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
Endometriosis
BMP-6 and SMAD4 gene expression is altered in cumulus cells from women with endometriosis-associated infertility.
Endotoxemia
Caspase-8 Collaborates with Caspase-11 to Drive Tissue Damage and Execution of Endotoxic Shock.
Epilepsy
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epilepsy
Overexpressed microRNA-494 represses RIPK1 to attenuate hippocampal neuron injury in epilepsy rats by inactivating the NF-?B signaling pathway.
Epilepsy, Temporal Lobe
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epistaxis
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
Epistaxis
Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality.
Epistaxis
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
Epistaxis
Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.
Epistaxis
Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
Epistaxis
Thoracic endografting in a patient with hereditary hemorrhagic telangiectasia presenting with a descending thoracic aneurysm.
Epistaxis
[Gene diagnosis and treatment of hereditary hemorrhagic telangiectasia with epistaxis as its main symptom].
Esophageal Neoplasms
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer.
Esophageal Neoplasms
Receptor interactive protein kinase 3 promotes Cisplatin-triggered necrosis in apoptosis-resistant esophageal squamous cell carcinoma cells.
Esophageal Squamous Cell Carcinoma
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway.
Essential Hypertension
Association of the gene polymorphisms of BMPR2, ACVRL1, SMAD9 and their interactions with the risk of essential hypertension in the Chinese Han population.
Extranodal Extension
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Eye Abnormalities
Distinct developmental programs require different levels of Bmp signaling during mouse retinal development.
Familial Primary Pulmonary Hypertension
15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation.
Familial Primary Pulmonary Hypertension
4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.
Familial Primary Pulmonary Hypertension
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
Familial Primary Pulmonary Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Familial Primary Pulmonary Hypertension
A potential functional association between mutant BMPR2 and primary ovarian insufficiency.
Familial Primary Pulmonary Hypertension
Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia.
Familial Primary Pulmonary Hypertension
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Familial Primary Pulmonary Hypertension
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
BMPR2 Mutation-independent Mechanisms of Disrupted BMP Signaling in IPAH.
Familial Primary Pulmonary Hypertension
BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein receptor-II mutation Arg491Trp causes malignant phenotype of familial primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Familial Primary Pulmonary Hypertension
Comparative analysis of BMPR2 gene and its mutations in idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
Familial Primary Pulmonary Hypertension
CORRIGENDUM: Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells.
Familial Primary Pulmonary Hypertension
De novo mutations in the BMPR2 gene in patients with heritable pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Developments in therapeutics for pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1.
Familial Primary Pulmonary Hypertension
Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Echocardiographic screening discloses increased values of pulmonary artery systolic pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic telangiectasia.
Familial Primary Pulmonary Hypertension
Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.
Familial Primary Pulmonary Hypertension
Extensive pulmonary sarcoid reaction in a patient with BMPR-2 associated idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein tùype II receptor.
Familial Primary Pulmonary Hypertension
Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.
Familial Primary Pulmonary Hypertension
Generation of a floxed allele of the mouse BMP type II receptor gene.
Familial Primary Pulmonary Hypertension
Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Growth, development, and phenotypic spectrum of individuals with deletions of 2q33.1 involving SATB2.
Familial Primary Pulmonary Hypertension
Heritable pulmonary hypertension: from bench to bedside.
Familial Primary Pulmonary Hypertension
Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium.
Familial Primary Pulmonary Hypertension
HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.
Familial Primary Pulmonary Hypertension
Hypermethylation of BMPR2 Promoter Occurs in the Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression.
Familial Primary Pulmonary Hypertension
Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.
Familial Primary Pulmonary Hypertension
Identities and frequencies of BMPR2 mutations in Chinese patients with idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: A case report.
Familial Primary Pulmonary Hypertension
Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.
Familial Primary Pulmonary Hypertension
Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Missense Mutations of the BMPR1B (ALK6) Gene in Childhood Idiopathic Pulmonary Arterial Hypertension.
Familial Primary Pulmonary Hypertension
Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.
Familial Primary Pulmonary Hypertension
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Familial Primary Pulmonary Hypertension
Monocrotaline pyrrole induces Smad nuclear accumulation and altered signaling expression in human pulmonary arterial endothelial cells.
Familial Primary Pulmonary Hypertension
Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
Familial Primary Pulmonary Hypertension
N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.
Familial Primary Pulmonary Hypertension
Novel nonsense mutation of the BMPR-II gene in a Japanese patient with familial primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers.
Familial Primary Pulmonary Hypertension
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Familial Primary Pulmonary Hypertension
Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.
Familial Primary Pulmonary Hypertension
Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31.
Familial Primary Pulmonary Hypertension
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
Familial Primary Pulmonary Hypertension
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Familial Primary Pulmonary Hypertension
Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Familial Primary Pulmonary Hypertension
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
Familial Primary Pulmonary Hypertension
The BMP type II receptor is located in lipid rafts, including caveolae, of pulmonary endothelium in vivo and in vitro.
Familial Primary Pulmonary Hypertension
The transforming growth factor-?-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease.
Familial Primary Pulmonary Hypertension
Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited.
Familial Primary Pulmonary Hypertension
Transforming growth factor-betas and vascular disorders.
Familial Primary Pulmonary Hypertension
Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
[Pulmonary hypertension: pathophysiology, genetics and functional genomics]
Fatty Liver
Inhibition of MLKL Attenuates Necroptotic Cell Death in a Murine Cell Model of Ischaemia Injury.
Fatty Liver
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.
Fatty Liver
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
Fetal Death
BMPR2 is required for postimplantation uterine function and pregnancy maintenance.
Fetal Growth Retardation
Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction.
Fibroadenoma
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Fibroma
Paratesticular fibrous pseudotumor: a morphologic and immunohistochemical study of 13 cases.
Foot Ulcer
Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers.
Gallbladder Neoplasms
Smac mimetic promotes TNF-? to induce apoptosis of gallbladder carcinoma cells.
Gastrointestinal Neoplasms
Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic human gastrointestinal cancer.
Genetic Diseases, Inborn
ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia.
Genetic Diseases, Inborn
Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Genetic Diseases, Inborn
Non-invasive CT screening for pulmonary arteriovenous malformations in children with confirmed hereditary hemorrhagic telangiectasia: Results from two pediatric centers.
Genetic Diseases, Inborn
Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT.
Genetic Diseases, Inborn
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
Genetic Diseases, Inborn
The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway.
Genetic Diseases, Inborn
Transforming growth factor ?--at the centre of systemic sclerosis.
Gestational Trophoblastic Disease
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Gingival Overgrowth
Expression of transforming growth factor-beta receptor II mRNA in cyclosporine-induced gingival overgrowth.
Glaucoma
A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model.
Glaucoma
Evaluation of Chitosan/Aptamer Targeting TGF-? Receptor II Thermo-Sensitive Gel for Scarring in Rat Glaucoma Filtration Surgery.
Glaucoma
Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders.
Glaucoma
Thermoreversible gel for delivery of activin receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery.
Glioblastoma
Integrative Network Analysis Combined with Quantitative Phosphoproteomics Reveals Transforming Growth Factor-beta Receptor type-2 (TGFBR2) as a Novel Regulator of Glioblastoma Stem Cell Properties.
Glioblastoma
Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells.
Glioblastoma
Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations.
Glioblastoma
Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
Glioma
A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression.
Glioma
Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma.
Glioma
Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1.
Glioma
Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations.
Glioma
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Glioma
Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.
Glioma
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
Glioma
Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells.
Glioma
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Glioma
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Glioma
Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-?.
Glioma
RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
Glioma
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.
Glioma
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Glioma
Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
Glomerulonephritis, IGA
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Glomerulonephritis, Membranoproliferative
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Glomerulonephritis, Membranous
Immunoelectron microscopic study on type I, II and III TGF-beta receptors on visceral glomerular epithelial cells in relation to glomerular basement membrane alterations in proteinuric rats.
Glucose Intolerance
The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance.
Gout
PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling.
Granuloma
RIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense.
Granuloma
[Influence of interferon gamma treatment on expression of TGF-beta1 and its receptors in liver fibrosis of mice with schistosomiasis japonica]
Graves Disease
Functional assessment of the BMPR2 gene in lymphoblastoid cell lines from Graves' disease patients.
Head and Neck Neoplasms
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
Head and Neck Neoplasms
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Heart Defects, Congenital
5'UTR Repeat Polymorphisms of the BMPR2 gene in Children with Pulmonary Hypertension associated with Congenital Heart Disease.
Heart Defects, Congenital
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Heart Defects, Congenital
BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease.
Heart Defects, Congenital
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
Heart Defects, Congenital
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
Heart Defects, Congenital
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Heart Defects, Congenital
Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension.
Heart Diseases
Changes in plasma levels of RIPK1, RIPK3, and MLKL in patients with coronary atherosclerotic heart disease and its clinical predictive value.
Heart Diseases
Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
Heart Diseases
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Heart Failure
Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.
Heart Failure
Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart.
Heart Failure
Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension.
Heart Failure
Reduced activin receptor-like kinase 1 activity promotes cardiac fibrosis in heart failure.
Heart Failure
RIPK3 Induces Cardiomyocyte Necroptosis via Inhibition of AMPK-Parkin-Mitophagy in Cardiac Remodelling after Myocardial Infarction.
Heart Septal Defects, Atrial
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
Heart Septal Defects, Atrial
The Efficacy of a Genetic Analysis of the BMPR2 Gene in a Patient with Severe Pulmonary Arterial Hypertension and an Atrial Septal Defect Treated with Bilateral Lung Transplantation.
Hemochromatosis
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Hemochromatosis
The hemochromatosis protein HFE signals predominantly via the BMP type I receptor ALK3 in vivo.
Hemoptysis
Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension.
Hepatitis
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
Hepatitis
RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
Hepatitis
Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
Hepatitis
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
Hepatitis A
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
Hepatitis B
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
Hepatitis B
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
Hepatitis B, Chronic
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
Hepatitis B, Chronic
[The expression of transforming growth factor-beta receptor I and its mRNA in liver tissues of chronic hepatitis B and the clinical significance]
Hepatitis C, Chronic
Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats.
Hepatitis C, Chronic
Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
Hernias, Diaphragmatic, Congenital
Mutations in BMPR2 are not present in patients with pulmonary hypertension associated with congenital diaphragmatic hernia.
Herpes Zoster
Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand.
Herpesviridae Infections
Remarkably Robust Antiviral Immune Response despite Combined Deficiency in Caspase-8 and RIPK3.
Hydatidiform Mole
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Hydrocephalus
Evidence for the involvement of caspases in establishing proper cerebrospinal fluid hydrodynamics.
Hyperandrogenism
Alteration of TGFB1, GDF9, and BMPR2 gene expression in preantral follicles of an estradiol valerate-induced polycystic ovary mouse model can lead to anovulation, polycystic morphology, obesity, and absence of hyperandrogenism.
Hyperandrogenism
Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.
Hypercholesterolemia
Increased type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge.
Hyperglycemia
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Hyperglycemia
Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.
Hyperinsulinism
Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.
Hyperlipidemias
[Hyperlipidemia induced by high fat diet ingestion activates TGF-beta/Smad signaling pathway in the kidney of diabetic rats]
Hypersensitivity
A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.
Hypertension
15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation.
Hypertension
4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.
Hypertension
5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: A meta-analysis.
Hypertension
A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension.
Hypertension
A dual-light reporter system to determine the efficiency of protein-protein interactions in mammalian cells.
Hypertension
A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian.
Hypertension
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Hypertension
A novel break point of the BMPR2 gene exonic deletion in a patient with pulmonary arterial hypertension.
Hypertension
A novel mutation in the BMPR2 gene in familial pulmonary arterial hypertension.
Hypertension
A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.
Hypertension
A potential functional association between mutant BMPR2 and primary ovarian insufficiency.
Hypertension
Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension.
Hypertension
Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.
Hypertension
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
Hypertension
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
Hypertension
Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
Hypertension
AN HOMOZYGOUS MUTATION IN KCNK3 IS ASSOCIATED WITH AN AGGRESSIVE FORM OF HEREDITARY PULMONARY ARTERIAL HYPERTENSION.
Hypertension
Approaches to treat pulmonary arterial hypertension by targeting bmpr2 - from cell membrane to nucleus.
Hypertension
BMP and activin type-II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
Hypertension
BMPR-II mutations promote pulmonary arterial hypertension via a hyperinflammatory response.
Hypertension
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
Hypertension
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
Hypertension
Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Hypertension
BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension.
Hypertension
BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients.
Hypertension
BMPR2 Mutation Carriers: Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension Without Symptoms: Cautionary Tales?
Hypertension
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
Hypertension
BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.
Hypertension
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
Hypertension
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
Hypertension
BMPR2 Mutations Influence Phenotype More Obviously in Male Patients with Pulmonary Arterial Hypertension.
Hypertension
BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients.
Hypertension
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
Hypertension
Bone morphogenetic protein receptor II is a novel mediator of eNOS activation.
Hypertension
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Hypertension
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Hypertension
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Hypertension
Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension.
Hypertension
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Hypertension
Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.
Hypertension
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Hypertension
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Hypertension
Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension.
Hypertension
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.
Hypertension
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
Hypertension
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
Hypertension
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Hypertension
Comparative analysis of BMPR2 gene and its mutations in idiopathic pulmonary arterial hypertension.
Hypertension
Connectivity Map Analysis of NMD+ BMPR2 Related HPAH Provides Insights into Disease Penetrance.
Hypertension
Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.
Hypertension
Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia.
Hypertension
Contributions of BMPR2 Mutations and Extrinsic Factors to Cellular Phenotypes of Pulmonary Arterial Hypertension Revealed by iPSC Modeling.
Hypertension
Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.
Hypertension
Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension.
Hypertension
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
Hypertension
Correlation Between Single Nucleotide Polymorphisms of the rs664589 Locus in the Long-Chain Noncoding RNA Lung Adenocarcinoma Metastasis-Associated Gene 1, Hypertension, and Its Mechanism.
Hypertension
CORRIGENDUM: Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
Hypertension
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Hypertension
Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells.
Hypertension
De novo mutations in the BMPR2 gene in patients with heritable pulmonary arterial hypertension.
Hypertension
Deletion of the sequence encoding the tail domain of the bone morphogenetic protein type 2 receptor reveals a bone morphogenetic protein 7-specific gain of function.
Hypertension
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Hypertension
Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension.
Hypertension
Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.
Hypertension
Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Hypertension
Early onset severe pulmonary arterial hypertension with 'two-hit' digenic mutations in both BMPR2 and KCNA5 genes.
Hypertension
Echocardiographic screening discloses increased values of pulmonary artery systolic pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic telangiectasia.
Hypertension
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Hypertension
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Hypertension
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
Hypertension
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling.
Hypertension
Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma.
Hypertension
Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.
Hypertension
EXPRESS: BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension.
Hypertension
Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.
Hypertension
Extensive pulmonary sarcoid reaction in a patient with BMPR-2 associated idiopathic pulmonary arterial hypertension.
Hypertension
Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue.
Hypertension
Function of Adipose-Derived Mesenchymal Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension through miR-191 via Regulation of BMPR2.
Hypertension
Functional mutations in 5'UTR of the BMPR2 gene identified in Chinese families with pulmonary arterial hypertension.
Hypertension
Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.
Hypertension
Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance.
Hypertension
Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene.
Hypertension
Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
Hypertension
Genetic variants in the Polish population of patients with pulmonary arterial hypertension - sequencing of BMPR2, ALK1 and ENG genes.
Hypertension
Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.
Hypertension
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Hypertension
Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.
Hypertension
High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension.
Hypertension
Hypermethylation of BMPR2 Promoter Occurs in the Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression.
Hypertension
Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.
Hypertension
Hypoxia-Induced Pulmonary Hypertension in Different Mouse Strains - Relation to Transcriptome.
Hypertension
Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.
Hypertension
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Hypertension
Identification of multiple ACVRL1 mutations in patients with pulmonary arterial hypertension by targeted exome capture.
Hypertension
Identities and frequencies of BMPR2 mutations in Chinese patients with idiopathic pulmonary arterial hypertension.
Hypertension
Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression.
Hypertension
Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: A case report.
Hypertension
Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension.
Hypertension
Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade.
Hypertension
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
Hypertension
In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and its Target Slug.
Hypertension
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.
Hypertension
Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.
Hypertension
Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Hypertension
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
Hypertension
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Hypertension
Loss-of BMPR2 is Associated With Abnormal DNA Repair in Pulmonary Arterial Hypertension.
Hypertension
Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension.
Hypertension
LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR? Activation.
Hypertension
Mate-pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension.
Hypertension
Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.
Hypertension
Methylation Analysis of the BMPR2 Gene Promoter Region in Patients With Pulmonary Arterial Hypertension.
Hypertension
Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions.
Hypertension
Missense Mutations of the BMPR1B (ALK6) Gene in Childhood Idiopathic Pulmonary Arterial Hypertension.
Hypertension
Modulation of Endothelial BMPR2 Activity by VEGFR3 in Pulmonary Arterial Hypertension.
Hypertension
Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.
Hypertension
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Hypertension
Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.
Hypertension
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension.
Hypertension
Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.
Hypertension
Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension.
Hypertension
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Hypertension
N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.
Hypertension
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.
Hypertension
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Hypertension
Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.
Hypertension
Novel promoter and exon mutations of the BMPR2 gene in Chinese patients with pulmonary arterial hypertension.
Hypertension
Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers.
Hypertension
Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
Hypertension
Oxidative stress increases M1dG, a major peroxidation-derived DNA adduct, in mitochondrial DNA.
Hypertension
Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.
Hypertension
Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.
Hypertension
PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation.
Hypertension
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
Hypertension
PPAR?-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Hypertension
Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation.
Hypertension
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Hypertension
Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension.
Hypertension
Pulmonary arterial hypertension associated with hereditary spherocytosis and splenectomy in a patient with a mutation in the BMPR2 gene.
Hypertension
Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient.
Hypertension
Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene.
Hypertension
Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis.
Hypertension
Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?
Hypertension
Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.
Hypertension
Pulmonary Vascular Platform Models the Effects of Flow and Pressure on Endothelial Dysfunction in BMPR2 Associated Pulmonary Arterial Hypertension.
Hypertension
Redox and Inflammatory Signaling, the Unfolded Protein Response, and the Pathogenesis of Pulmonary Hypertension.
Hypertension
Regulation of bone morphogenetic protein signalling in human pulmonary vascular development.
Hypertension
Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
Hypertension
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.
Hypertension
Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.
Hypertension
Right ventricular and pulmonary vascular reserve in asymptomatic BMPR2 mutation carriers.
Hypertension
RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Hypertension
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
Hypertension
SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension.
Hypertension
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Hypertension
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Hypertension
Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.
Hypertension
Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Hypertension
Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Hypertension
Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension.
Hypertension
Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension.
Hypertension
Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization.
Hypertension
Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertension.
Hypertension
SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
Hypertension
Subcellular mechanisms in pulmonary arterial hypertension: combinatorial modalities that inhibit anterograde trafficking and cause bone morphogenetic protein receptor type 2 mislocalization.
Hypertension
Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension.
Hypertension
Targeting BMPR2 Trafficking with Chaperones: An Important Step toward Precision Medicine in Pulmonary Arterial Hypertension.
Hypertension
Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension.
Hypertension
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
Hypertension
TGF? and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
Hypertension
The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension.
Hypertension
The Efficacy of a Genetic Analysis of the BMPR2 Gene in a Patient with Severe Pulmonary Arterial Hypertension and an Atrial Septal Defect Treated with Bilateral Lung Transplantation.
Hypertension
The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population.
Hypertension
The P2-receptor-mediated Ca2+ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension.
Hypertension
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension.
Hypertension
The transforming growth factor-?-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease.
Hypertension
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
Hypertension
Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited.
Hypertension
Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood.
Hypertension
Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.
Hypertension
Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension.
Hypertension
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
Hypertension
[Bone morphogenetic protein type II receptor gene promoter mutation-142G > A in a patient with familial pulmonary arterial hypertension]
Hypertension, Portal
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Hypertension, Pulmonary
17?-Estradiol and estrogen receptor ? protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.
Hypertension, Pulmonary
5'UTR Repeat Polymorphisms of the BMPR2 gene in Children with Pulmonary Hypertension associated with Congenital Heart Disease.
Hypertension, Pulmonary
A Case of Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.
Hypertension, Pulmonary
A novel BMPR2 gene mutation associated with exercise-induced pulmonary hypertension in septal defects.
Hypertension, Pulmonary
Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension.
Hypertension, Pulmonary
Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Hypertension, Pulmonary
AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension.
Hypertension, Pulmonary
Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II.
Hypertension, Pulmonary
BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia.
Hypertension, Pulmonary
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
Hypertension, Pulmonary
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Hypertension, Pulmonary
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.
Hypertension, Pulmonary
Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Hypertension, Pulmonary
BMPR2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension.
Hypertension, Pulmonary
BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension.
Hypertension, Pulmonary
BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
Hypertension, Pulmonary
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Hypertension, Pulmonary
CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Hypertension, Pulmonary
Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.
Hypertension, Pulmonary
Chloroquine Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Lysosomal Bmpr-II Degradation.
Hypertension, Pulmonary
Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice.
Hypertension, Pulmonary
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
Hypertension, Pulmonary
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.
Hypertension, Pulmonary
Combination use of sildenafil and simvastatin increases BMPR-II signal transduction in rats with monocrotaline-mediated pulmonary hypertension.
Hypertension, Pulmonary
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Hypertension, Pulmonary
Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.
Hypertension, Pulmonary
Estrogen Metabolite 16?-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.
Hypertension, Pulmonary
Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.
Hypertension, Pulmonary
Extensive pulmonary sarcoid reaction in a patient with BMPR-2 associated idiopathic pulmonary arterial hypertension.
Hypertension, Pulmonary
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
Hypertension, Pulmonary
Genetic counselling in a national referral centre for pulmonary hypertension.
Hypertension, Pulmonary
Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.
Hypertension, Pulmonary
HMGB1/TLR4 promotes hypoxic pulmonary hypertension via suppressing BMPR2 signaling.
Hypertension, Pulmonary
Hyperoxia Synergizes with Mutant BMPR2 to Cause Metabolic Stress, Oxidant Injury, and Pulmonary Hypertension.
Hypertension, Pulmonary
Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.
Hypertension, Pulmonary
Immunolocalisation of BMPR-II and TGF-Ã type I and II receptors in primary plexogenic pulmonary hypertension.
Hypertension, Pulmonary
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.
Hypertension, Pulmonary
Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
Hypertension, Pulmonary
Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle.
Hypertension, Pulmonary
Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway.
Hypertension, Pulmonary
Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Hypertension, Pulmonary
Longitudinal Analysis Casts Doubt on the Presence of Genetic Anticipation in Heritable Pulmonary Arterial Hypertension.
Hypertension, Pulmonary
Modification of hemodynamic and immune responses to exposure with a weak antigen by the expression of a hypomorphic BMPR2 gene.
Hypertension, Pulmonary
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Hypertension, Pulmonary
Mutations in BMPR2 are not present in patients with pulmonary hypertension associated with congenital diaphragmatic hernia.
Hypertension, Pulmonary
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Hypertension, Pulmonary
Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies.
Hypertension, Pulmonary
Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension.
Hypertension, Pulmonary
Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.
Hypertension, Pulmonary
Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.
Hypertension, Pulmonary
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
Hypertension, Pulmonary
Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry.
Hypertension, Pulmonary
Pulmonary arterial hypertension associated with hereditary spherocytosis and splenectomy in a patient with a mutation in the BMPR2 gene.
Hypertension, Pulmonary
Pulmonary arterial hypertension-associated genetic variants in combined post-capillary and pre-capillary pulmonary hypertension: a case report.
Hypertension, Pulmonary
Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?
Hypertension, Pulmonary
Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.
Hypertension, Pulmonary
Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease).
Hypertension, Pulmonary
Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.
Hypertension, Pulmonary
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.
Hypertension, Pulmonary
Rho-kinase Inhibition Alleviates Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative Type II Bone Morphogenetic Protein Receptor Gene.
Hypertension, Pulmonary
Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension.
Hypertension, Pulmonary
Screening asymptomatic BMPR2 mutation carriers: a new frontier for pulmonary hypertension physicians?
Hypertension, Pulmonary
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Hypertension, Pulmonary
Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case-control study.
Hypertension, Pulmonary
SMAD1 Deficiency in Either Endothelial or Smooth Muscle Cells Can Predispose Mice to Pulmonary Hypertension.
Hypertension, Pulmonary
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
Hypertension, Pulmonary
SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
Hypertension, Pulmonary
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Hypertension, Pulmonary
Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension.
Hypertension, Pulmonary
TWIST1 Drives Smooth Muscle Cell Proliferation in Pulmonary Hypertension via Loss of GATA-6 and BMPR2.
Hypertrophy, Right Ventricular
Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Hypertrophy, Right Ventricular
AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension.
Hypertrophy, Right Ventricular
Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2.
Hypertrophy, Right Ventricular
Elevated pulmonary arterial pressure in Zucker diabetic fatty rats.
Hypertrophy, Right Ventricular
Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Hypertrophy, Right Ventricular
Targeted gene delivery of BMPR-2 attenuates pulmonary hypertension.
Hypospadias
Molecular and toxicologic research in newborn hypospadiac male rats following in utero exposure to di-n-butyl phthalate (DBP).
Hypothyroidism
Deletion of 14.7?Mb 2q32.3q33.3 with a marfanoid phenotype and hypothyroidism.
Hypothyroidism
Hepatocyte 'priming' and increase in transforming growth factor-beta1 mRNA expression are delayed in hypothyroid versus euthyroid rats during liver regeneration.
Idiopathic Pulmonary Fibrosis
Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient.
Immunoglobulin G4-Related Disease
ALK-1 Positive Orbital Inflammatory Myofibroblastic Tumour (IMT) Associated with Prominent Numbers of IgG4 Plasma Cells-A Case Report.
Infarction, Middle Cerebral Artery
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
Infections
A cysteine-rich receptor-like protein kinase CaCKR5 modulates immune response against Ralstonia solanacearum infection in pepper.
Infections
A leucine-rich repeat receptor-like protein kinase (LRPKm1) gene is induced in Malus x domestica by Venturia inaequalis infection and salicylic acid treatment.
Infections
An S-locus receptor-like kinase plays a role as a negative regulator in plant defense responses.
Infections
Bacterial meningitis: the role of transforming growth factor-Beta in innate immunity and secondary brain damage.
Infections
Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection.
Infections
DAI Senses Influenza A Virus Genomic RNA and Activates RIPK3-Dependent Cell Death.
Infections
Dectin-1-induced RIPK1 and RIPK3 activation protects host against Candida albicans infection.
Infections
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
Infections
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
Infections
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
Infections
HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.
Infections
Human Rhinovirus 3C protease cleaves RIPK1, concurrent with caspase 8 activation.
Infections
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Infections
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Infections
Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3.
Infections
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Infections
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Infections
Necroptosis Promotes Staphylococcus aureus Clearance by Inhibiting Excessive Inflammatory Signaling.
Infections
Newly Identified Function of Caspase-6 in ZBP1-mediated Innate Immune Responses, NLRP3 Inflammasome Activation, PANoptosis, and Host Defense.
Infections
p38(MAPK)/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection.
Infections
Real-Time Induction of Macrophage Apoptosis, Pyroptosis, and Necroptosis by Enterococcus faecalis OG1RF and Two Root Canal Isolated Strains.
Infections
Receptor-interacting serine/threonine kinase 1- and 3-dependent inflammation induced in lungs of chicken infected with Pasteurella multocida.
Infections
Rhinovirus 3C protease suppresses apoptosis and triggers caspase-independent cell death.
Infections
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
Infections
RIPK3 Is Largely Dispensable for RIG-I-Like Receptor- and Type I Interferon-Driven Transcriptional Responses to Influenza A Virus in Murine Fibroblasts.
Infections
Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome.
Infections
RIPK3-Dependent Recruitment of Low-Inflammatory Myeloid Cells Does Not Protect from Systemic Salmonella Infection.
Infections
RIPK3/Fas-Associated Death Domain Axis Regulates Pulmonary Immunopathology to Cryptococcal Infection Independent of Necroptosis.
Infections
Role and Regulation of Nodal/Activin Receptor-Like Kinase 7 Signaling Pathway in the Control of Ovarian Follicular Atresia.
Infections
RSV Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells.
Infections
Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation.
Infections
Species-independent contribution of ZBP1/DAI/DLM-1-triggered necroptosis in host defense against HSV1.
Infections
Temporal and spatial assessment of defence responses in resistant and susceptible hop cultivars during infection with Verticillium nonalfalfae.
Infections
The latest information on the RIPK1 post-translational modifications and functions.
Infections
Therapeutic contribution of melatonin to the treatment of septic cardiomyopathy: A novel mechanism linking Ripk3-modified mitochondrial performance and endoplasmic reticulum function.
Infections
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection.
Infections
Type I IFNs drive hematopoietic stem and progenitor cell collapse via impaired proliferation and increased RIPK1-dependent cell death during shock-like ehrlichial infection.
Infections
Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL.
Infertility
BMP-6 and SMAD4 gene expression is altered in cumulus cells from women with endometriosis-associated infertility.
Infertility, Female
BMPR2 is required for postimplantation uterine function and pregnancy maintenance.
Inflammatory Bowel Diseases
ABIN3 negatively regulates necroptosis-induced intestinal inflammation through recruiting A20 and restricting the ubiquitination of RIPK3 in inflammatory bowel disease.
Inflammatory Bowel Diseases
Analyzing Necroptosis Using an RIPK1 Kinase Inactive Mouse Model of TNF Shock.
Inflammatory Bowel Diseases
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Inflammatory Bowel Diseases
Emerging views of mitophagy in immunity and autoimmune diseases.
Inflammatory Bowel Diseases
Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases.
Inflammatory Bowel Diseases
Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients.
Inflammatory Bowel Diseases
Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Inflammatory Bowel Diseases
Publisher Correction: Death by inflammation: drug makers chase the master controller.
Inflammatory Bowel Diseases
The scaffold-dependent function of RIPK1 in dendritic cells promotes injury-induced colitis.
Influenza, Human
Analysis of Cytokine- and Influenza A Virus-Driven RIPK3 Necrosome Formation.
Influenza, Human
RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus.
Influenza, Human
RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection.
Influenza, Human
RIPK3 Is Largely Dispensable for RIG-I-Like Receptor- and Type I Interferon-Driven Transcriptional Responses to Influenza A Virus in Murine Fibroblasts.
Influenza, Human
The Z?2 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development.
Influenza, Human
Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL.
Insulin Resistance
PPAR? is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis.
Insulin Resistance
RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice.
Insulin Resistance
RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
Insulin Resistance
The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance.
Intellectual Disability
The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis.
Intervertebral Disc Degeneration
Developing consistently reproducible intervertebral disc degeneration at rat caudal spine by using needle puncture.
Intervertebral Disc Degeneration
High BMPR2 expression leads to enhanced SMAD1/5/8 signalling and GDF6 responsiveness in human adipose-derived stem cells: implications for stem cell therapies for intervertebral disc degeneration.
Intervertebral Disc Degeneration
RIPK1 suppresses apoptosis mediated by TNF and caspase-3 in intervertebral discs.
Intervertebral Disc Degeneration
Role of growth differentiation factor-5 and bone morphogenetic protein type II receptor in the development of lumbar intervertebral disc degeneration.
Intervertebral Disc Displacement
Transforming growth factor beta receptor induction in herniated intervertebral disc tissue: an immunohistochemical study.
Intestinal Neoplasms
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
Intracranial Aneurysm
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Aneurysm
Endoglin is not a major susceptibility gene for intracranial aneurysm among Japanese.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Invasive Fungal Infections
RIPK3/Fas-Associated Death Domain Axis Regulates Pulmonary Immunopathology to Cryptococcal Infection Independent of Necroptosis.
Iron Overload
Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice.
Iron Overload
ROS-Mediated Necroptosis Is Involved in Iron Overload-Induced Osteoblastic Cell Death.
Ischemic Stroke
Caspofungin Suppresses Brain Cell Necroptosis in Ischemic Stroke Rats via Up-Regulation of Pellino3.
Ischemic Stroke
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
Ischemic Stroke
Necrostatin-1 Prevents Necroptosis in Brains after Ischemic Stroke via Inhibition of RIPK1-Mediated RIPK3/MLKL Signaling.
Keloid
A novel truncated TGF-beta receptor II downregulates collagen synthesis and TGF-beta I secretion of keloid fibroblasts.
Keloid
Blocking transforming growth factor-beta receptor signaling down-regulates transforming growth factor-beta1 autoproduction in keloid fibroblasts.
Keloid
Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells.
Keloid
Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts.
Keloid
Genetic susceptibility to keloid disease: transforming growth factor beta receptor gene polymorphisms are not associated with keloid disease.
Keloid
SB-431542 inhibits TGF-beta-induced contraction of collagen gel by normal and keloid fibroblasts.
Keratosis, Actinic
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Keratosis, Seborrheic
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Keratosis, Seborrheic
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Leiomyoma
Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells.
Leiomyosarcoma
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder.
Leiomyosarcoma
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Leukemia
Association between CASP7 and CASP14 genetic polymorphisms and the risk of childhood leukemia.
Leukemia
Expression of cyclin A and bone morphogenetic protein receptors and response to induction therapy in patients with acute leukemias.
Leukemia
Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.
Leukemia
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
Leukemia
[Expression and significance of TGF-beta1, TbetaRII and c-myc in patients with acute leukemia]
Leukemia
[Identification of the isoform in type II receptor of transforming growth factor-beta in patients with acute leukemia and its clinical significance]
Leukemia, Lymphocytic, Chronic, B-Cell
The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor.
Leukemia, Mast-Cell
Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.
Leukemia, Myeloid, Acute
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
Leukemia, Myeloid, Acute
[Correlation of NK cell RIPK1 with Prognosis of Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].
Leukemia-Lymphoma, Adult T-Cell
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).
Leukodystrophy, Globoid Cell
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Lichen Planus, Oral
ALK1 expression in oral lichen planus: a possible relation to microvessel density.
Liver Cirrhosis
Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat.
Liver Cirrhosis
Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy.
Liver Cirrhosis
Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
Liver Cirrhosis
Kaempferol attenuates liver fibrosis by inhibiting activin receptor-like kinase 5.
Liver Cirrhosis
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Liver Cirrhosis
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
Liver Cirrhosis
TGF-? Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1?-Induced Epithelial Mesenchymal Transition.
Liver Cirrhosis
Transforming growth factor betas and their receptors in human liver cirrhosis.
Liver Cirrhosis
[Effects of antisense transforming growth factor beta receptor-I expressing plasmid on pig serum-induced rat liver fibrosis]
Liver Cirrhosis
[Influence of interferon gamma treatment on expression of TGF-beta1 and its receptors in liver fibrosis of mice with schistosomiasis japonica]
Liver Cirrhosis, Biliary
Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.
Liver Cirrhosis, Biliary
B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Beta-glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis.
Liver Cirrhosis, Biliary
Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
Liver Diseases
Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome.
Liver Diseases
Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.
Liver Diseases
Differential expression of transforming growth factor-beta and its receptors in hepatocytes and nonparenchymal cells of rat liver after CCl4 administration.
Liver Diseases
I?B kinase?/? control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1.
Liver Diseases
Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8.
Liver Diseases
JNK signaling prevents biliary cyst formation through a CASPASE-8-dependent function of RIPK1 during aging.
Liver Diseases
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
Liver Diseases
RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.
Liver Diseases
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
Liver Diseases
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
Liver Neoplasms
Effects of siRNA targeting BMPR-II on the biological activities of human liver cancer cells and its mechanism.
Loeys-Dietz Syndrome
A case of near total aortic replacement in an adolescent with loeys-dietz syndrome.
Loeys-Dietz Syndrome
A Japanese family of typical Loeys-Dietz syndrome with a TGFBR2 mutation.
Loeys-Dietz Syndrome
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Loeys-Dietz Syndrome
Generation of an induced pluripotent stem cell line from a Loeys-Dietz syndrome patient with transforming growth factor-beta receptor-2 gene mutation.
Loeys-Dietz Syndrome
Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome.
Loeys-Dietz Syndrome
High prevalence of vertebral artery tortuosity of Loeys-Dietz syndrome in comparison with Marfan syndrome.
Loeys-Dietz Syndrome
Loeys-Dietz syndrome in pregnancy: a case description and report of a novel mutation.
Loeys-Dietz Syndrome
Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity.
Loeys-Dietz Syndrome
Surgical Experience With Aggressive Aortic Pathologic Process in Loeys-Dietz Syndrome.
Loeys-Dietz Syndrome
Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome.
Loeys-Dietz Syndrome
The differences in surgical long-term outcomes between Marfan syndrome and Loeys-Dietz syndrome.
Loeys-Dietz Syndrome
[Marfan-like aortic aneurysm syndrome; A surgical experience with Loeys-Dietz syndrome]
Lung Injury
Deficiency of receptor-interacting protein kinase 3 (RIPK3) attenuates inflammation and organ injury in neonatal sepsis.
Lung Injury
Expression of transforming growth factor-beta type I and type II receptors is altered in rat lungs undergoing bleomycin-induced pulmonary fibrosis.
Lung Injury
Inhibition of activin receptor-like kinase 5 induces matrix metallopeptidase 9 expression and aggravates lipopolysaccharide-induced pulmonary injury in mice.
Lung Injury
Receptor-interacting serine/threonine kinase 1- and 3-dependent inflammation induced in lungs of chicken infected with Pasteurella multocida.
Lung Injury
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection.
Lung Injury
TREM-1 Attenuates RIPK3 Mediated Necroptosis in Hyperoxia Induced Lung Injury in Neonatal Mice.
Lung Neoplasms
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.
Lung Neoplasms
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
Lung Neoplasms
CNOT3 contributes to cisplatin resistance in lung cancer through inhibiting RIPK3 expression.
Lung Neoplasms
Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines.
Lung Neoplasms
Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines.
Lung Neoplasms
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
Lung Neoplasms
MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma.
Lung Neoplasms
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Lung Neoplasms
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells.
Lung Neoplasms
Single-nucleotide polymorphism rs17548629 in RIPK1 gene may be associated with lung cancer in a young and middle-aged Han Chinese population.
Lung Neoplasms
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
Lupus Erythematosus, Systemic
Emerging views of mitophagy in immunity and autoimmune diseases.
Lupus Nephritis
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Lupus Nephritis
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Lymphadenopathy
A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.
Lymphadenopathy
The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.
Lymphatic Metastasis
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Lymphatic Metastasis
Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.
Lymphatic Metastasis
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Lymphatic Metastasis
RIPK3 Suppresses the Progression of Spontaneous Intestinal Tumorigenesis.
Lymphatic Metastasis
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Lymphatic Metastasis
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Lymphatic Metastasis
[Functional significance of TGF-beta1 signal transduction pathway in oral squamous cell carcinoma]
Lymphedema
EW-7197, a Transforming Growth Factor-Beta Type I Receptor Kinase Inhibitor, Ameliorates Acquired Lymphedema in a Mouse Tail Model.
Lymphoma
24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
Lymphoma
A Case of Secondary Sclerosing Cholangitis in the setting of Non-Hodgkin's Lymphoma.
Lymphoma
A Comparative Study of Inflammatory Myofibroblastic Tumors and Tumefactive IgG4-related Inflammatory Lesions: the Relevance of IgG4 Plasma Cells.
Lymphoma
A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.
Lymphoma
Aggressive presentation of breast implant-associated ALK-1 negative anaplastic large cell lymphoma with bilateral axillary lymph node involvement.
Lymphoma
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Lymphoma
Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature.
Lymphoma
Anaplastic lymphoma of the cervical esophagus presenting as a tracheoesophageal fistula.
Lymphoma
Association of Marek's Disease induced immunosuppression with activation of a novel regulatory T cells in chickens.
Lymphoma
Bone marrow involvement in systemic alk+ anaplastic large cell lymphoma: morphological resemblance with hodgkin s lymphoma.
Lymphoma
Case report: A unique pediatric case of a primary CD8 expressing ALK-1 positive anaplastic large cell lymphoma of skeletal muscle.
Lymphoma
CD5- and CD23-positive splenic diffuse large B-cell lymphoma with very low CD20 expression.
Lymphoma
Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status: Case Reports and Review of Literature.
Lymphoma
Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach.
Lymphoma
Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
Lymphoma
Fine needle aspiration cytology of ALK 1(-), CD 30(+) anaplastic large cell lymphoma post renal transplantation: A case report and literature review.
Lymphoma
Granulomatous slack skin mycosis fungoides developing simultaneously with sarcoid-like lesions in a patient with repeated anabolic injections in the past?
Lymphoma
Identification of a novel common proviral integration site, flit-1, in feline leukemia virus induced thymic lymphoma.
Lymphoma
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells.
Lymphoma
MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability.
Lymphoma
Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archival tissue.
Lymphoma
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression.
Lymphoma
Primary hepatic Epstein-Barr virus-associated CD30-positive peripheral T-cell lymphoma of cytotoxic phenotype.
Lymphoma
Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand.
Lymphoma
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Lymphoma
Transforming growth factor-beta1 effects on endothelial monolayer permeability involve focal adhesion kinase/Src.
Lymphoma
[ALK-1 positive anaplastic large cell lymphoma of the lung. Report of a pediatric case]
Lymphoma, B-Cell
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma.
Lymphoma, B-Cell
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
Lymphoma, B-Cell
Effects of prostaglandin F2? (PGF2?) on cell-death pathways in the bovine corpus luteum (CL).
Lymphoma, B-Cell
Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines.
Lymphoma, B-Cell
[Marfan syndrome complicated with CD5+ CD10+ diffuse large B-cell lymphoma]
Lymphoma, Large B-Cell, Diffuse
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.
Lymphoma, Large-Cell, Anaplastic
Aggressive presentation of breast implant-associated ALK-1 negative anaplastic large cell lymphoma with bilateral axillary lymph node involvement.
Lymphoma, Large-Cell, Anaplastic
Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature.
Lymphoma, Large-Cell, Anaplastic
Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology.
Lymphoma, Large-Cell, Anaplastic
Bone marrow involvement in systemic alk+ anaplastic large cell lymphoma: morphological resemblance with hodgkin s lymphoma.
Lymphoma, Large-Cell, Anaplastic
Case report: A unique pediatric case of a primary CD8 expressing ALK-1 positive anaplastic large cell lymphoma of skeletal muscle.
Lymphoma, Large-Cell, Anaplastic
Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status: Case Reports and Review of Literature.
Lymphoma, Large-Cell, Anaplastic
Histiocytic sarcoma of the cavernous sinus: case report and literature review.
Lymphoma, Large-Cell, Anaplastic
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression.
Lymphoma, Large-Cell, Anaplastic
[ALK-1 positive anaplastic large cell lymphoma of the lung. Report of a pediatric case]
Lymphoma, T-Cell
Loss of receptors for transforming growth factor beta in human T-cell malignancies.
Lymphoma, T-Cell, Cutaneous
A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.
Lymphoproliferative Disorders
EMA and ALK-1 Immunostaining in Cutaneous CD30+ Lymphoproliferative Disorders.
Marfan Syndrome
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Marfan Syndrome
Phenotypic heterogeneity of Marfan-like connective tissue disorders associated with mutations in the transforming growth factor-beta receptor genes.
Marfan Syndrome
Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity.
Marfan Syndrome
The differences in surgical long-term outcomes between Marfan syndrome and Loeys-Dietz syndrome.
Massive Hepatic Necrosis
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
Melanoma
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Melanoma
Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury.
Melanoma
Divergence(s) in nodal signaling between aggressive melanoma and embryonic stem cells.
Melanoma
In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.
Melanoma
RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy.
Melanoma
TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma.
Memory Disorders
RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.
Meningioma
Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells.
Meningitis
Bacterial meningitis: the role of transforming growth factor-Beta in innate immunity and secondary brain damage.
Mesothelioma
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Mesothelioma, Malignant
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Mesothelioma, Malignant
Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
Metabolic Diseases
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
Mixed Connective Tissue Disease
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Mucocutaneous Lymph Node Syndrome
[Association of single nucleotide polymorphism in TGFBR2 gene with Kawasaki disease and coronary artery lesions].
Multiple Myeloma
Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.
Multiple Sclerosis
RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis.
Muscle Spasticity
Hereditary spastic paraplegia-causing mutations in atlastin-1 interfere with BMPRII trafficking.
Myocardial Infarction
Correction to: MicroRNA-325-3p protects the heart after myocardial infarction by inhibiting RIPK3 and programmed necrosis in mice.
Myocardial Infarction
Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro.
Myocardial Infarction
MicroRNA-325-3p protects the heart after myocardial infarction by inhibiting RIPK3 and programmed necrosis in mice.
Myocardial Infarction
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Myocardial Infarction
RIPK3 Induces Cardiomyocyte Necroptosis via Inhibition of AMPK-Parkin-Mitophagy in Cardiac Remodelling after Myocardial Infarction.
Myocardial Infarction
Ripk3 mediates cardiomyocyte necrosis through targeting mitochondria and the JNK-Bnip3 pathway under hypoxia-reoxygenation injury.
Myocardial Infarction
Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention.
Myocardial Infarction
Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.
Myocardial Infarction
The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873.
Myocardial Ischemia
Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
Myositis Ossificans
A Novel Factor, Tmem176b, Induced by Activin-like Kinase 2 Signal Promotes the Differentiation of Myoblasts into Osteoblasts.
Myositis Ossificans
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.
Myositis Ossificans
A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
Myositis Ossificans
ALK2 R206H Mutation Linked to Fibrodysplasia Ossificans Progressiva Confers Constitutive Activity to the BMP Type I Receptor and Sensitizes Mesenchymal Cells to BMP-Induced Osteoblast Differentiation and Bone Formation.
Myositis Ossificans
Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic ?-catenin degradation.
Myositis Ossificans
In vitro Analyses of the Dysregulated R206H ALK2 Kinase-FKBP12 Interaction Associated with Heterotopic Ossification in FOP.
Myositis Ossificans
Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Myositis Ossificans
Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Myositis Ossificans
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches.
Myositis Ossificans
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Myositis Ossificans
The role of the 3'UTR region in the regulation of the ACVR1/Alk-2 gene expression.
Myositis Ossificans
The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway.
Myositis Ossificans
Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
Neonatal Sepsis
Deficiency of receptor-interacting protein kinase 3 (RIPK3) attenuates inflammation and organ injury in neonatal sepsis.
Neoplasm Metastasis
Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.
Neoplasm Metastasis
ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells.
Neoplasm Metastasis
ALK7 Promotes Vascular Smooth Muscle Cells Phenotypic Modulation by Negative Regulating PPAR? Expression.
Neoplasm Metastasis
Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone.
Neoplasm Metastasis
BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells.
Neoplasm Metastasis
BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma.
Neoplasm Metastasis
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
Neoplasm Metastasis
BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.
Neoplasm Metastasis
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.
Neoplasm Metastasis
Breast Cancer Special Feature: Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.
Neoplasm Metastasis
C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer.
Neoplasm Metastasis
Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center.
Neoplasm Metastasis
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Neoplasm Metastasis
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Neoplasm Metastasis
Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Neoplasm Metastasis
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Neoplasm Metastasis
EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Neoplasm Metastasis
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Neoplasm Metastasis
Identification of miR-135b as a novel regulator of TGF? pathway in gastric cancer.
Neoplasm Metastasis
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Neoplasm Metastasis
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Neoplasm Metastasis
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
Neoplasm Metastasis
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
Neoplasm Metastasis
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Neoplasm Metastasis
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Neoplasm Metastasis
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
Neoplasm Metastasis
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.
Neoplasm Metastasis
Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases.
Neoplasm Metastasis
Nucleolar and Spindle Associated Protein 1 (NUSAP1) Promotes Bladder Cancer Progression Through the TGF-? Signaling Pathway.
Neoplasm Metastasis
p130Cas is required for mammary tumor growth and transforming growth factor-{beta} (TGF-{beta})-mediated metastasis through regulation of Smad2/3 activity.
Neoplasm Metastasis
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Neoplasm Metastasis
Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.
Neoplasm Metastasis
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Neoplasm Metastasis
Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis.
Neoplasm Metastasis
Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway.
Neoplasm Metastasis
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis.
Neoplasm Metastasis
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Neoplasm Metastasis
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
Neoplasm Metastasis
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Neoplasm Metastasis
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
Neoplasm Metastasis
The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice.
Neoplasm Metastasis
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Neoplasm Metastasis
The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling.
Neoplasm Metastasis
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
Neoplasm Metastasis
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Neoplasm Metastasis
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Neoplasm Metastasis
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Neoplasm Metastasis
Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis.
Neoplasm Metastasis
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Neoplasm Metastasis
[Functional significance of TGF-beta1 signal transduction pathway in oral squamous cell carcinoma]
Neoplasms
24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
Neoplasms
3-O-acetylrubianol C (3AR-C) induces RIPK1-dependent programmed cell death by selective inhibition of IKK?.
Neoplasms
8-Geranylumbelliferone isolated from Paramignya trimera triggers RIPK1/RIPK3-dependent programmed cell death upon TNFR1 ligation.
Neoplasms
?Np63?-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.
Neoplasms
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
Neoplasms
A Comparative Study of Inflammatory Myofibroblastic Tumors and Tumefactive IgG4-related Inflammatory Lesions: the Relevance of IgG4 Plasma Cells.
Neoplasms
A critical role for transcription factor Smad4 in T cell function that is independent of transforming growth factor ? receptor signaling.
Neoplasms
A cytosolic heat shock protein 90 and co-chaperone p23 complex activates RIPK3/MLKL during necroptosis of endothelial cells in acute respiratory distress syndrome.
Neoplasms
A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.
Neoplasms
A dual role for Caspase8 and NF-?B interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival.
Neoplasms
A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression.
Neoplasms
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Neoplasms
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
Neoplasms
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
Neoplasms
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.
Neoplasms
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
Neoplasms
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
Neoplasms
A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
Neoplasms
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Neoplasms
Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.
Neoplasms
Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.
Neoplasms
Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors.
Neoplasms
Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca.
Neoplasms
Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis.
Neoplasms
Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer.
Neoplasms
Activated human B cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return.
Neoplasms
Activin receptor-like kinase 1 is associated with immune cell infiltration and regulates CLEC14A transcription in cancer.
Neoplasms
Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Neoplasms
Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.
Neoplasms
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
Neoplasms
ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer.
Neoplasms
ALK-1 Positive Orbital Inflammatory Myofibroblastic Tumour (IMT) Associated with Prominent Numbers of IgG4 Plasma Cells-A Case Report.
Neoplasms
ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.
Neoplasms
Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Neoplasms
Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic human gastrointestinal cancer.
Neoplasms
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
Neoplasms
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
Neoplasms
Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases.
Neoplasms
Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
Neoplasms
Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor.
Neoplasms
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
Neoplasms
Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination.
Neoplasms
Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation.
Neoplasms
Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells.
Neoplasms
Blastic plasmacytoid dendritic cell neoplasm presenting as fever with diffuse cutaneous nodules.
Neoplasms
Blockade of transforming growth factor-beta (TGF?) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line.
Neoplasms
BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells.
Neoplasms
BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.
Neoplasms
BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer.
Neoplasms
BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma.
Neoplasms
BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells.
Neoplasms
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
Neoplasms
BMPR2 promotes fatty acid oxidation and protects white adipocytes from cell death in mice.
Neoplasms
BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma.
Neoplasms
Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-?-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.
Neoplasms
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Neoplasms
Breast Cancer Special Feature: Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.
Neoplasms
c-Jun N-terminal kinases differentially regulate TNF- and TLRs-mediated necroptosis through their kinase-dependent and -independent activities.
Neoplasms
Casein kinase-1?1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3.
Neoplasms
Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening.
Neoplasms
Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells.
Neoplasms
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Neoplasms
Chlamydia trachomatis fails to protect its growth niche against pro-apoptotic insults.
Neoplasms
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
Neoplasms
Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.
Neoplasms
Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center.
Neoplasms
Collision Tumor Composed of an Inflammatory Myofibroblastic Tumor and Adenocarcinoma of the Colon: a Rare Entity.
Neoplasms
Computational analyses of interactions between ALK-5 and bioactive ligands: insights for the design of potential anticancer agents.
Neoplasms
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer.
Neoplasms
Conversion of normal human oral keratinocytes to tumorigenic cells is associated with the acquisition of resistance to TGF-beta.
Neoplasms
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Neoplasms
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Neoplasms
Cytomorphology of ALK+ anaplastic large cell lymphoma displaying spindle cells mimicking a sarcomatous tumor: Report of a case.
Neoplasms
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Neoplasms
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Neoplasms
Decreased RIPK1 expression in chondrocytes alleviates osteoarthritis via the TRIF/MyD88-RIPK1-TRAF2 negative feedback loop.
Neoplasms
Dedifferentiated Liposarcoma With Inflammatory Myofibroblastic Tumor-like Features.
Neoplasms
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Neoplasms
Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells.
Neoplasms
Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
Neoplasms
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
Neoplasms
DIABLO/SMAC mimetics selectively kill HIV-1-infected resting memory CD4+ T cells: a potential role in a cure strategy for HIV-1 infection.
Neoplasms
Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
Neoplasms
Differential expression of and responsiveness to transforming growth factor-beta (TGF-beta) isoforms in hormone-dependent and independent lines of mouse mammary tumors.
Neoplasms
Differentiation of malignant oral rat keratinocytes reflects changes in EGF and TGF-beta receptor expression but not growth factor dependence.
Neoplasms
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-? type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Neoplasms
Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Neoplasms
Downregulation of bone morphogenetic protein receptor 2 promotes the development of neuroblastoma.
Neoplasms
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Neoplasms
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Neoplasms
Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Neoplasms
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.
Neoplasms
Epithelial HMGB1 Delays Skin Wound Healing and Drives Tumor Initiation by Priming Neutrophils for NET Formation.
Neoplasms
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
Neoplasms
EW-7197, an oral transforming growth factor ? type I receptor kinase inhibitor, for preventing peritoneal adhesion formation in a rat model.
Neoplasms
Expression and genetic polymorphism of necroptosis related protein RIPK1 is correlated with severe hepatic ischemia-reperfusion injury and prognosis after hepatectomy in hepatocellular carcinoma patients.
Neoplasms
Expression of a new type high molecular weight receptor (type V receptor) of transforming growth factor beta in normal and transformed cells.
Neoplasms
Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy.
Neoplasms
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Neoplasms
Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
Neoplasms
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Neoplasms
Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer.
Neoplasms
Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
Neoplasms
Expression of TGF-beta type II receptor antisense RNA impairs TGF-beta signaling in vitro and promotes mammary gland differentiation in vivo.
Neoplasms
Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma.
Neoplasms
Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
Neoplasms
Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane.
Neoplasms
Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Neoplasms
Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Neoplasms
Expression of Transforming Growth Factor-beta Receptors and Related Cell-Cycle Components in Transitional-Cell Carcinoma of the Bladder.
Neoplasms
Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules.
Neoplasms
Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
Neoplasms
FADD and Caspase-8 Regulate Gut Homeostasis and Inflammation by Controlling MLKL- and GSDMD-Mediated Death of Intestinal Epithelial Cells.
Neoplasms
Featured Article: microRNA-125a in pulmonary hypertension: Regulator of a proliferative phenotype of endothelial cells.
Neoplasms
Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Neoplasms
FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
Neoplasms
Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells.
Neoplasms
Furosine, a Maillard Reaction Product, Triggers Necroptosis in Hepatocytes by Regulating the RIPK1/RIPK3/MLKL Pathway.
Neoplasms
G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program.
Neoplasms
Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes.
Neoplasms
Gene expression of cytokine receptors in HL60 cells exposed to a 50 Hz magnetic field.
Neoplasms
Gene expression of transforming growth factor beta receptors I and II in non-small-cell lung tumors.
Neoplasms
Genetic alterations in the transforming growth factor receptor complex in sporadic endometrial carcinoma.
Neoplasms
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
Neoplasms
Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice.
Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Neoplasms
Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.
Neoplasms
Genipin ameliorates diet-induced obesity via promoting lipid mobilization and browning of white adipose tissue in rats.
Neoplasms
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Neoplasms
Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma.
Neoplasms
Growth inhibition of a human lymphoma cell line: induction of a transforming growth factor-beta-mediated autocrine negative loop by phorbol myristate acetate.
Neoplasms
Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis.
Neoplasms
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Neoplasms
Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
Neoplasms
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.
Neoplasms
Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.
Neoplasms
Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.
Neoplasms
Hypoxia upregulates adhesion ability to peritoneum through a transforming growth factor-beta-dependent mechanism in diffuse-type gastric cancer cells.
Neoplasms
I?B kinase?/? control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1.
Neoplasms
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Neoplasms
Identification of a novel common proviral integration site, flit-1, in feline leukemia virus induced thymic lymphoma.
Neoplasms
Identification of miR-135b as a novel regulator of TGF? pathway in gastric cancer.
Neoplasms
Identification of PCTA, a TGIF antagonist that promotes PML function in TGF-beta signalling.
Neoplasms
IFN-gamma and TNF-alpha inhibit expression of TGF-beta-1, its receptors TBETAR-I and TBETAR-II in the corpus luteum of PMSG/hCG treated rhesus monkey.
Neoplasms
IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?
Neoplasms
Immunocytochemical features of lens after cataract tissue--signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins.
Neoplasms
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
Neoplasms
In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis.
Neoplasms
In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.
Neoplasms
Increased expression of TGF-beta1 reduces tumor growth of human U-87 Glioblastoma Cells in vivo.
Neoplasms
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases.
Neoplasms
Increased TGFbeta type II receptor expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells.
Neoplasms
Inducing regulated necrosis and shifting macrophage polarization with anti-EMMPRIN antibody (161-pAb) and complement factors.
Neoplasms
Inflammatory myofibroblastic tumor of the trachea with concomitant granulomatous lymph node lesions.
Neoplasms
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Neoplasms
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors.
Neoplasms
Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis.
Neoplasms
Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
Neoplasms
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
Neoplasms
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Neoplasms
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
Neoplasms
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
Neoplasms
Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
Neoplasms
Interferon-? induces the cell surface exposure of phosphatidylserine by activating the protein MLKL in the absence of caspase-8 activity.
Neoplasms
Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity.
Neoplasms
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
Neoplasms
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Neoplasms
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
Neoplasms
Lack of frameshift mutations at coding mononucleotide repeats in hepatocellular carcinoma in Japanese patients.
Neoplasms
Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.
Neoplasms
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Neoplasms
Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.
Neoplasms
Loss of growth regulation by transforming growth factor-beta (TGF-beta) in human cancers: studies on endometrial carcinoma.
Neoplasms
Loss of receptors for transforming growth factor beta in human T-cell malignancies.
Neoplasms
Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Neoplasms
Low-grade abdominopelvic sarcoma with myofibroblastic features (low-grade myofibroblastic sarcoma): clinicopathological, immunohistochemical, molecular genetic and ultrastructural study of two cases with literature review.
Neoplasms
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.
Neoplasms
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
Neoplasms
Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.
Neoplasms
Malignant cells, directors of the malignant process: role of transforming growth factor-beta.
Neoplasms
MicroRNA-381-3p Functions as a Dual Suppressor of Apoptosis and Necroptosis and Promotes Proliferation of Renal Cancer Cells.
Neoplasms
MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development.
Neoplasms
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.
Neoplasms
Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population.
Neoplasms
miR-100-3p inhibits cell proliferation and induces apoptosis in human gastric cancer through targeting to BMPR2.
Neoplasms
Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms.
Neoplasms
Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis.
Neoplasms
More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
Neoplasms
MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability.
Neoplasms
MUC13 protects colorectal cancer cells from death by activating the NF-?B pathway and is a potential therapeutic target.
Neoplasms
Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archival tissue.
Neoplasms
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Neoplasms
Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma.
Neoplasms
Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas.
Neoplasms
Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer.
Neoplasms
Myeloid tumor necrosis factor and heme oxygenase-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
Neoplasms
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.
Neoplasms
Neutrophil-rich anaplastic large cell lymphoma of the skull presenting after head trauma.
Neoplasms
Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases.
Neoplasms
Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II.
Neoplasms
Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization.
Neoplasms
Novel Transforming Growth Factor-Beta Receptor 1 Antagonists through a Pharmacophore-Based Virtual Screening Approach.
Neoplasms
Ophiopogonin D', a Natural Product From Radix Ophiopogonis, Induces in Vitro and in Vivo RIPK1-Dependent and Caspase-Independent Apoptotic Death in Androgen-Independent Human Prostate Cancer Cells.
Neoplasms
Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells.
Neoplasms
P7170: a novel molecule with unique profile of mTORC1/C2 and Activin Receptor-Like Kinase 1 inhibition leading to anti-tumor and anti-angiogenic activity.
Neoplasms
Paratesticular fibrous pseudotumor: a morphologic and immunohistochemical study of 13 cases.
Neoplasms
Parotid Gland Solitary Fibrous Tumor: A Case Report and Clinicopathologic Review of 22 Cases from the Literature.
Neoplasms
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.
Neoplasms
Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Neoplasms
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Neoplasms
Plasmablastic lymphoma may occur as a high-grade transformation from plasmacytoma.
Neoplasms
Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage.
Neoplasms
Primary anaplastic large cell lymphoma in the dura of the brain: case report and prediction of a favorable prognosis.
Neoplasms
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression.
Neoplasms
Primary CD30/ALK-1 positive anaplastic large cell lymphoma of the skeletal muscle in a child.
Neoplasms
Primary Gastric ALK-negative EBV-negative Anaplastic Large Cell Lymphoma Presenting with Iron Deficiency Anemia.
Neoplasms
Primary mediastinal anaplastic alk-1-positive large-cell lymphoma of T/NK-cell type expressing CD20.
Neoplasms
Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.
Neoplasms
Prognostic implications of BAX and TGFBRII mutations in colon cancers with microsatellite instability.
Neoplasms
Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations.
Neoplasms
Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients.
Neoplasms
Programmed necrosis - a new mechanism of steroidogenic luteal cell death and elimination during luteolysis in cows.
Neoplasms
Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand.
Neoplasms
Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases.
Neoplasms
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Neoplasms
Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.
Neoplasms
Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.
Neoplasms
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Neoplasms
Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma.
Neoplasms
Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway.
Neoplasms
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Neoplasms
Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells.
Neoplasms
Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling.
Neoplasms
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.
Neoplasms
Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability.
Neoplasms
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells.
Neoplasms
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Neoplasms
Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Neoplasms
RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression.
Neoplasms
RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis.
Neoplasms
RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
Neoplasms
RIPK1 polymorphisms alter the susceptibility to cervical Cancer among the Uyghur population in China.
Neoplasms
RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.
Neoplasms
RIPK1 suppresses apoptosis mediated by TNF and caspase-3 in intervertebral discs.
Neoplasms
RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function.
Neoplasms
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment.
Neoplasms
RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition.
Neoplasms
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Neoplasms
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
Neoplasms
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Neoplasms
RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
Neoplasms
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
Neoplasms
RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence.
Neoplasms
RIPK3-Mediated Necroptosis Promotes Donor Kidney Inflammatory Injury and Reduces Allograft Survival.
Neoplasms
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.
Neoplasms
Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells.
Neoplasms
Shortened ALK1 regulatory fragment maintains a specific activity in arteries feeding ischemic tissues.
Neoplasms
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
Neoplasms
Sinonasal IgG4-related disease: a rare and emerging entity broadening the differential diagnosis in the sinonasal universe.
Neoplasms
Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Neoplasms
Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein.
Neoplasms
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Neoplasms
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Neoplasms
Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
Neoplasms
Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability.
Neoplasms
Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex.
Neoplasms
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Neoplasms
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma.
Neoplasms
Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).
Neoplasms
Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38? MAP inhibitors.
Neoplasms
TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling.
Neoplasms
TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Neoplasms
TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
Neoplasms
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Neoplasms
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
Neoplasms
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
Neoplasms
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
Neoplasms
Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer.
Neoplasms
The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer.
Neoplasms
The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers.
Neoplasms
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Neoplasms
The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study.
Neoplasms
The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature.
Neoplasms
The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling.
Neoplasms
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
Neoplasms
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Neoplasms
The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study.
Neoplasms
The Trend of ripk1/ripk3 and mlkl Mediated Necroptosis Pathway in Patients with Different Stages of Prostate Cancer as Promising Progression Biomarkers.
Neoplasms
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
Neoplasms
The type III TGF-{beta} receptor regulates epithelial and cancer cell migration through {beta}-arrestin2-mediated activation of Cdc42.
Neoplasms
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Neoplasms
The upregulation of expressed proteins in HepG2 cells transfected by the recombinant plasmid-containing HBx gene.
Neoplasms
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Neoplasms
TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy.
Neoplasms
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection.
Neoplasms
TNF? drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.
Neoplasms
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Neoplasms
Transforming growth factor beta receptors in verrucous and squamous cell carcinoma.
Neoplasms
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.
Neoplasms
Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression.
Neoplasms
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Neoplasms
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Neoplasms
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia.
Neoplasms
Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth.
Neoplasms
Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes.
Neoplasms
Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor.
Neoplasms
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
Neoplasms
Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation.
Neoplasms
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.
Neoplasms
Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells.
Neoplasms
Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation.
Neoplasms
Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Neoplasms
Tubular epithelial cells in renal clear cell carcinoma express high RIPK1/3 and show increased susceptibility to TNF receptor 1-induced necroptosis.
Neoplasms
Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.
Neoplasms
Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Neoplasms
Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-beta receptor expression and altered responses to these growth factors.
Neoplasms
Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis.
Neoplasms
Uncommon TGFBRI allele is not associated with increased susceptibility to colon cancer.
Neoplasms
Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene.
Neoplasms
Upregulation of transforming growth factor-beta type I receptor by interferon consensus sequence-binding protein in osteosarcoma cells.
Neoplasms
Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Neoplasms
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Neoplasms
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Neoplasms
Widespread mitochondrial depletion via mitophagy does not compromise necroptosis.
Neoplasms
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Neoplasms
[Expression and clinical significance of receptor-interacting protein serine-threonine kinases 1 in the nucleus pulposus of patients with lumbar disc herniation].
Neoplasms
[Functional significance of TGF-beta1 signal transduction pathway in oral squamous cell carcinoma]
Neoplasms
[Identification of the isoform in type II receptor of transforming growth factor-beta in patients with acute leukemia and its clinical significance]
Neoplasms
[Mechanism of resistance to growth inhibition by transforming growth factor-beta 1 (TGF-beta 1) in primary lung cancer and new molecular targets in therapy]
Nephritis
Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression.
Nephritis
Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis.
Nephritis
Immune-Mediated Nephropathy and Systemic Autoimmunity in Mice Does Not Require Receptor Interacting Protein Kinase 3 (RIPK3).
Nephritis
Immunoelectron microscopic study on type I, II and III TGF-beta receptors on visceral glomerular epithelial cells in relation to glomerular basement membrane alterations in proteinuric rats.
Nephritis
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Nephritis
Transforming growth factor-beta receptors in self-limited vs. chronic progressive nephritis in rats.
Nephrosis
Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy.
Nephrosis, Lipoid
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Nesidioblastosis
Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression.
Neuroblastoma
24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
Neuroblastoma
Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy.
Neuroblastoma
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Neuroblastoma
Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas.
Neuroinflammatory Diseases
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Neuroinflammatory Diseases
Inhibiting RIPK1 Limits Neuroinflammation and Alleviates Postoperative Cognitive Impairments in D-Galactose-Induced Aged Mice.
Neuroinflammatory Diseases
Inhibition of microglial receptor-interacting protein kinase 1 ameliorates neuroinflammation following cerebral ischaemic stroke.
Neuroinflammatory Diseases
Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.
Neuroinflammatory Diseases
Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-?-cyclodextrin.
Neuroinflammatory Diseases
NEK1-mediated retromer trafficking promotes blood-brain barrier integrity by regulating glucose metabolism and RIPK1 activation.
Neuroinflammatory Diseases
Outcomes of RIP Kinase Signaling During Neuroinvasive Viral Infection.
Neuroinflammatory Diseases
RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis.
Neuroinflammatory Diseases
RIPK3 Promotes JEV Replication in Neurons via Downregulation of IFI44L.
Neuroinflammatory Diseases
RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.
Neuroinflammatory Diseases
TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging.
Neuroma, Acoustic
Expression of transforming growth factor-beta receptor type 1 and type 2 in human sporadic vestibular Schwannoma.
Non-alcoholic Fatty Liver Disease
ATP Citrate Lyase and LncRNA NONMMUT010685 Play Crucial Role in Nonalcoholic Fatty Liver Disease Based on Analysis of Microarray Data.
Non-alcoholic Fatty Liver Disease
Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8.
Non-alcoholic Fatty Liver Disease
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
RIPK1 targeting protects against obesity and atherosclerosis.
Non-alcoholic Fatty Liver Disease
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
non-specific protein-tyrosine kinase deficiency
c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression.
Non-ST Elevated Myocardial Infarction
Changes in plasma levels of RIPK1, RIPK3, and MLKL in patients with coronary atherosclerotic heart disease and its clinical predictive value.
Obesity
Activin Receptor-like Kinase 7 Suppresses Lipolysis to Accumulate Fat in Obesity Through Downregulation of Peroxisome Proliferator-Activated Receptor ? and C/EBP?
Obesity
Alteration of TGFB1, GDF9, and BMPR2 gene expression in preantral follicles of an estradiol valerate-induced polycystic ovary mouse model can lead to anovulation, polycystic morphology, obesity, and absence of hyperandrogenism.
Obesity
Genetic and evolutionary analyses of the human bone morphogenetic protein receptor 2 (BMPR2) in the pathophysiology of obesity.
Obesity
Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression.
Obesity
Publisher Correction: RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice.
Obesity
RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice.
Obstetric Labor, Premature
Differential expression of transforming growth factor-beta 1 and transforming growth factor-beta receptors in myometrium of women with failed induction of labor, no labor, and preterm labor.
Odontogenic Tumors
Immunoexpression of BMP-2 and BMP-4 and their receptors, BMPR-IA and BMPR-II, in ameloblastomas and adenomatoid odontogenic tumors.
Osteoarthritis
Cripto favors chondrocyte hypertrophy via TGF-? SMAD1/5 signaling during development of osteoarthritis.
Osteoarthritis
Decreased RIPK1 expression in chondrocytes alleviates osteoarthritis via the TRIF/MyD88-RIPK1-TRAF2 negative feedback loop.
Osteolysis
The effect of adenovirus-mediated siRNA targeting BMPR-II on UHMWPE-induced osteoclast formation.
Osteonecrosis
Exosomal miR-100-5p inhibits osteogenesis of hBMSCs and angiogenesis of HUVECs by suppressing the BMPR2/Smad1/5/9 signalling pathway.
Osteonecrosis
PPARgamma-2 and BMPR2 genes were differentially expressed in peripheral blood of SLE patients with osteonecrosis.
Osteonecrosis
PPARgamma-2 and BMPR2 Genes Were Significantly Differentially Expressed in Peripheral Blood of SLE Patients with Osteonecrosis.
Osteoporosis
Characterisation of genetic regulatory effects for osteoporosis risk variants in human osteoclasts.
Osteosarcoma
BMPR1A is necessary for chondrogenesis and osteogenesis, whereas BMPR1B prevents hypertrophic differentiation.
Osteosarcoma
BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma.
Osteosarcoma
BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.
Osteosarcoma
Inhibition of BMP receptor synthesis by antisense oligonucleotides attenuates OP-1 action in primary cultures of fetal rat calvaria cells.
Osteosarcoma
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
Osteosarcoma
Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells.
Osteosarcoma
Upregulation of transforming growth factor-beta type I receptor by interferon consensus sequence-binding protein in osteosarcoma cells.
Otosclerosis
Signaling by way of type IB and II bone morphogenetic protein receptors regulates bone formation in otospongiosis.
Ovarian Neoplasms
A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.
Ovarian Neoplasms
Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7.
Ovarian Neoplasms
Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Ovarian Neoplasms
Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
Ovarian Neoplasms
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Ovarian Neoplasms
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Ovarian Neoplasms
MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
Ovarian Neoplasms
Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells.
Ovarian Neoplasms
Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
Ovarian Neoplasms
TCEA3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells.
Ovarian Neoplasms
Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.
Ovarian Neoplasms
Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-? signaling.
Pancreatic Neoplasms
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Pancreatic Neoplasms
Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo.
Pancreatic Neoplasms
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.
Pancreatic Neoplasms
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Pancreatic Neoplasms
Interaction of Polymorphisms in Mitotic Regulator Genes With Cigarette Smoking and Pancreatic Cancer Risk.
Pancreatic Neoplasms
Ligand induced upregulation of the type II transforming growth factor (TGF-beta) receptor enhances TGF-beta responsiveness in COLO-357 cells.
Pancreatic Neoplasms
Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.
Pancreatic Neoplasms
Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage.
Pancreatic Neoplasms
Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Pancreatic Neoplasms
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
Pancreatic Neoplasms
Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer.
Pancreatic Neoplasms
Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex.
Pancreatic Neoplasms
Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells.
Pancreatitis
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Pancreatitis
Suppression of transforming growth factor beta signalling aborts caerulein induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations.
Pancreatitis, Chronic
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis.
Pancreatitis, Chronic
Fibrogenesis in alcoholic chronic pancreatitis: the role of tissue necrosis, macrophages, myofibroblasts and cytokines.
Paralysis
Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.
Paramyxoviridae Infections
Emerging views of mitophagy in immunity and autoimmune diseases.
Parkinson Disease
Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNF?-mediated apoptosis.
Parkinson Disease
RIPK1 inhibitor ameliorates the MPP+/MPTP-induced Parkinson's disease through the ASK1/JNK signalling pathway.
Penile Induration
IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease.
Penile Induration
Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease.
Perinatal Death
RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis.
Periodontitis
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Pheochromocytoma
Nerve growth factor mediates activation of the Smad pathway in PC12 cells.
Pituitary Neoplasms
Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-beta receptor type I and type II in human pituitary adenomas.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Pneumonia
Interventions and mechanisms of N-acetylcysteine on monocrotaline-induced pulmonary arterial hypertension.
Pneumonia
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
Pneumonia
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
Pneumonia
TBK1/IKK? Negatively Regulate LPS-Induced Neutrophil Necroptosis and Lung Inflammation.
Pneumonia
TREM-1 Attenuates RIPK3 Mediated Necroptosis in Hyperoxia Induced Lung Injury in Neonatal Mice.
Pneumonia, Pneumococcal
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
Pneumothorax
Expression of TGF-beta receptor 1 and Smads in the tissues of primary spontaneous pneumothorax.
Pneumovirus Infections
RSV Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells.
Polycystic Ovary Syndrome
Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.
Porcine Reproductive and Respiratory Syndrome
Molecular Markers of MDR of Chemotherapy for HSCC: Proteomic Screening With High-Throughput Liquid Chromatography-Tandem Mass Spectrometry.
Porcine Reproductive and Respiratory Syndrome
Viral strategies for triggering and manipulating mitophagy.
Poroma
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Pre-Eclampsia
Gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis-related genes ACVRL1 and EGFL7 in early-onset disease.
Pre-Eclampsia
Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction.
Pre-Eclampsia
Nodal signals through activin receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Expression and significance of TGF-beta1, TbetaRII and c-myc in patients with acute leukemia]
Primary Ovarian Insufficiency
A potential functional association between mutant BMPR2 and primary ovarian insufficiency.
Prolactinoma
Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas.
Prostatic Hyperplasia
Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Prostatic Hyperplasia
CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Prostatic Hyperplasia
Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression.
Prostatic Intraepithelial Neoplasia
Transforming growth factor-beta expression in prostate neoplasia.
Prostatic Neoplasms
Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Prostatic Neoplasms
Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
Prostatic Neoplasms
Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Prostatic Neoplasms
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.
Prostatic Neoplasms
Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
Prostatic Neoplasms
Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening.
Prostatic Neoplasms
CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Prostatic Neoplasms
Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells.
Prostatic Neoplasms
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Prostatic Neoplasms
Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Prostatic Neoplasms
Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
Prostatic Neoplasms
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Prostatic Neoplasms
Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP).
Prostatic Neoplasms
Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
Prostatic Neoplasms
miR-20b-5p, TGFBR2, and E2F1 Form a Regulatory Loop to Participate in Epithelial to Mesenchymal Transition in Prostate Cancer.
Prostatic Neoplasms
More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
Prostatic Neoplasms
Prohibitin and Cofilin Are Intracellular Effectors of Transforming Growth Factor {beta} Signaling in Human Prostate Cancer Cells.
Prostatic Neoplasms
Promoter methylation reduces expression of TGF-beta receptor type 2 gene in prostate cancer.
Prostatic Neoplasms
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study.
Prostatic Neoplasms
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Prostatic Neoplasms
Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study.
Prostatic Neoplasms
The Trend of ripk1/ripk3 and mlkl Mediated Necroptosis Pathway in Patients with Different Stages of Prostate Cancer as Promising Progression Biomarkers.
Prostatic Neoplasms
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Prostatic Neoplasms
Transforming growth factor-{beta} receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?
protein acetyllysine n-acetyltransferase deficiency
SIRT3 deficiency delays diabetic skin wound healing via oxidative stress and necroptosis enhancement.
protein acetyllysine n-acetyltransferase deficiency
Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation.
Psoriasis
Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis.
Psoriasis
Receptor-interacting Protein Kinase 3 Controls Keratinocyte Activation in a Necroptosis-independent Manner and Promotes Psoriatic Dermatitis in Mice.
Psoriasis
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
Pulmonary Arterial Hypertension
4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: A meta-analysis.
Pulmonary Arterial Hypertension
A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
A dual-light reporter system to determine the efficiency of protein-protein interactions in mammalian cells.
Pulmonary Arterial Hypertension
A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian.
Pulmonary Arterial Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Pulmonary Arterial Hypertension
A novel break point of the BMPR2 gene exonic deletion in a patient with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
A novel mutation in the BMPR2 gene in familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.
Pulmonary Arterial Hypertension
Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
Pulmonary Arterial Hypertension
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
AN HOMOZYGOUS MUTATION IN KCNK3 IS ASSOCIATED WITH AN AGGRESSIVE FORM OF HEREDITARY PULMONARY ARTERIAL HYPERTENSION.
Pulmonary Arterial Hypertension
Approaches to treat pulmonary arterial hypertension by targeting bmpr2 - from cell membrane to nucleus.
Pulmonary Arterial Hypertension
BMP and activin type-II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
Pulmonary Arterial Hypertension
BMP9 and BMP10: two close vascular quiescence partners that stand out.
Pulmonary Arterial Hypertension
BMPR-II mutations promote pulmonary arterial hypertension via a hyperinflammatory response.
Pulmonary Arterial Hypertension
BMPR2 expression is suppressed by signaling through the estrogen receptor.
Pulmonary Arterial Hypertension
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
Pulmonary Arterial Hypertension
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Pulmonary Arterial Hypertension
Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients.
Pulmonary Arterial Hypertension
BMPR2 Mutation Carriers: Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension Without Symptoms: Cautionary Tales?
Pulmonary Arterial Hypertension
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
Pulmonary Arterial Hypertension
BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
Pulmonary Arterial Hypertension
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
Pulmonary Arterial Hypertension
BMPR2 Mutations Influence Phenotype More Obviously in Male Patients with Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients.
Pulmonary Arterial Hypertension
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Bone morphogenetic protein receptor II is a novel mediator of eNOS activation.
Pulmonary Arterial Hypertension
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Pulmonary Arterial Hypertension
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Pulmonary Arterial Hypertension
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Pulmonary Arterial Hypertension
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Pulmonary Arterial Hypertension
Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.
Pulmonary Arterial Hypertension
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Pulmonary Arterial Hypertension
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Pulmonary Arterial Hypertension
Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.
Pulmonary Arterial Hypertension
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
Pulmonary Arterial Hypertension
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
Pulmonary Arterial Hypertension
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Connectivity Map Analysis of NMD+ BMPR2 Related HPAH Provides Insights into Disease Penetrance.
Pulmonary Arterial Hypertension
Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia.
Pulmonary Arterial Hypertension
Contributions of BMPR2 Mutations and Extrinsic Factors to Cellular Phenotypes of Pulmonary Arterial Hypertension Revealed by iPSC Modeling.
Pulmonary Arterial Hypertension
Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.
Pulmonary Arterial Hypertension
Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells.
Pulmonary Arterial Hypertension
Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2.
Pulmonary Arterial Hypertension
Deletion of the sequence encoding the tail domain of the bone morphogenetic protein type 2 receptor reveals a bone morphogenetic protein 7-specific gain of function.
Pulmonary Arterial Hypertension
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Pulmonary Arterial Hypertension
Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Early onset severe pulmonary arterial hypertension with 'two-hit' digenic mutations in both BMPR2 and KCNA5 genes.
Pulmonary Arterial Hypertension
Emerging role of bone morphogenetic proteins in angiogenesis.
Pulmonary Arterial Hypertension
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
Pulmonary Arterial Hypertension
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling.
Pulmonary Arterial Hypertension
Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma.
Pulmonary Arterial Hypertension
EXPRESS: BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue.
Pulmonary Arterial Hypertension
Function of Adipose-Derived Mesenchymal Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension through miR-191 via Regulation of BMPR2.
Pulmonary Arterial Hypertension
Functional mutations in 5'UTR of the BMPR2 gene identified in Chinese families with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.
Pulmonary Arterial Hypertension
Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance.
Pulmonary Arterial Hypertension
Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene.
Pulmonary Arterial Hypertension
Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Genetic counselling in a national referral centre for pulmonary hypertension.
Pulmonary Arterial Hypertension
Genetic variants in the Polish population of patients with pulmonary arterial hypertension - sequencing of BMPR2, ALK1 and ENG genes.
Pulmonary Arterial Hypertension
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Pulmonary Arterial Hypertension
Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.
Pulmonary Arterial Hypertension
High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.
Pulmonary Arterial Hypertension
Hypoxia-Induced Pulmonary Hypertension in Different Mouse Strains - Relation to Transcriptome.
Pulmonary Arterial Hypertension
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Pulmonary Arterial Hypertension
Identification of multiple ACVRL1 mutations in patients with pulmonary arterial hypertension by targeted exome capture.
Pulmonary Arterial Hypertension
Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression.
Pulmonary Arterial Hypertension
Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade.
Pulmonary Arterial Hypertension
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
Pulmonary Arterial Hypertension
In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and its Target Slug.
Pulmonary Arterial Hypertension
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.
Pulmonary Arterial Hypertension
Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Pulmonary Arterial Hypertension
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Loss-of BMPR2 is Associated With Abnormal DNA Repair in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR? Activation.
Pulmonary Arterial Hypertension
Mate-pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.
Pulmonary Arterial Hypertension
Methylation Analysis of the BMPR2 Gene Promoter Region in Patients With Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions.
Pulmonary Arterial Hypertension
Modulation of Endothelial BMPR2 Activity by VEGFR3 in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Pulmonary Arterial Hypertension
Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.
Pulmonary Arterial Hypertension
Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Mutations of NOTCH3 in childhood pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
New pathogenic variant of BMPR2 in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.
Pulmonary Arterial Hypertension
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Pulmonary Arterial Hypertension
Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Novel promoter and exon mutations of the BMPR2 gene in Chinese patients with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers.
Pulmonary Arterial Hypertension
Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Oxidative stress increases M1dG, a major peroxidation-derived DNA adduct, in mitochondrial DNA.
Pulmonary Arterial Hypertension
Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.
Pulmonary Arterial Hypertension
Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.
Pulmonary Arterial Hypertension
PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation.
Pulmonary Arterial Hypertension
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
Pulmonary Arterial Hypertension
PPAR?-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Pulmonary Arterial Hypertension
Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation.
Pulmonary Arterial Hypertension
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Pulmonary Arterial Hypertension
Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension associated with hereditary spherocytosis and splenectomy in a patient with a mutation in the BMPR2 gene.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient.
Pulmonary Arterial Hypertension
Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis.
Pulmonary Arterial Hypertension
Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?
Pulmonary Arterial Hypertension
Pulmonary hypertension in hereditary haemorrhagic telangiectasia.
Pulmonary Arterial Hypertension
Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.
Pulmonary Arterial Hypertension
Pulmonary Vascular Platform Models the Effects of Flow and Pressure on Endothelial Dysfunction in BMPR2 Associated Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Redox and Inflammatory Signaling, the Unfolded Protein Response, and the Pathogenesis of Pulmonary Hypertension.
Pulmonary Arterial Hypertension
Regulation of bone morphogenetic protein signalling in human pulmonary vascular development.
Pulmonary Arterial Hypertension
Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.
Pulmonary Arterial Hypertension
Right ventricular and pulmonary vascular reserve in asymptomatic BMPR2 mutation carriers.
Pulmonary Arterial Hypertension
RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Role of SMURF1 ubiquitin ligase in BMP receptor trafficking and signaling.
Pulmonary Arterial Hypertension
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
Pulmonary Arterial Hypertension
SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Significance of BMPR2 mutations in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization.
Pulmonary Arterial Hypertension
Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
Pulmonary Arterial Hypertension
Subcellular mechanisms in pulmonary arterial hypertension: combinatorial modalities that inhibit anterograde trafficking and cause bone morphogenetic protein receptor type 2 mislocalization.
Pulmonary Arterial Hypertension
Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Targeting BMPR2 Trafficking with Chaperones: An Important Step toward Precision Medicine in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
Pulmonary Arterial Hypertension
TGF? and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
The BMPR2 missense mutation p.K230N and pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
The Efficacy of a Genetic Analysis of the BMPR2 Gene in a Patient with Severe Pulmonary Arterial Hypertension and an Atrial Septal Defect Treated with Bilateral Lung Transplantation.
Pulmonary Arterial Hypertension
The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population.
Pulmonary Arterial Hypertension
The flavonoid quercetin reverses pulmonary hypertension in rats.
Pulmonary Arterial Hypertension
The P2-receptor-mediated Ca2+ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood.
Pulmonary Arterial Hypertension
What patients and their relatives think about testing for BMPR2.
Pulmonary Arterial Hypertension
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
Pulmonary Arterial Hypertension
[Bone morphogenetic protein type II receptor gene promoter mutation-142G > A in a patient with familial pulmonary arterial hypertension]
Pulmonary Arterial Hypertension
[Study of the BMPR2 gene in patients with pulmonary arterial hypertension]
Pulmonary Disease, Chronic Obstructive
A Functional Variant rs6435156C > T in BMPR2 is Associated With Increased Risk of Chronic Obstructive Pulmonary Disease (COPD) in Southern Chinese Population.
Pulmonary Disease, Chronic Obstructive
Necroptosis Signaling Promotes Inflammation, Airway Remodeling, and Emphysema in Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Smads as intracellular mediators of airway inflammation.
Pulmonary Embolism
Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise.
Pulmonary Embolism
High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension.
Pulmonary Fibrosis
A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis.
Pulmonary Fibrosis
Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.
Pulmonary Fibrosis
Expression of transforming growth factor-beta type I and type II receptors is altered in rat lungs undergoing bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
Necrostatin-1 Alleviates Bleomycin-Induced Pulmonary Fibrosis and Extracellular Matrix Expression in Interstitial Pulmonary Fibrosis.
Pulmonary Fibrosis
Progressive Transforming Growth Factor {beta}1-induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor.
Pulmonary Fibrosis
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis.
Pulmonary Veno-Occlusive Disease
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Pulmonary Veno-Occlusive Disease
Genetic counselling in a national referral centre for pulmonary hypertension.
receptor protein serine/threonine kinase deficiency
ABIN-1 regulates RIPK1 activation by linking Met1 ubiquitylation with Lys63 deubiquitylation in TNF-RSC.
receptor protein serine/threonine kinase deficiency
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.
receptor protein serine/threonine kinase deficiency
BMP type II receptor deficiency confers resistance to growth inhibition by TGF-? in pulmonary artery smooth muscle cells: role of proinflammatory cytokines.
receptor protein serine/threonine kinase deficiency
BMP-9 and LDL crosstalk regulates ALK-1 endocytosis and LDL transcytosis in endothelial cells.
receptor protein serine/threonine kinase deficiency
BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGF?-TAK1-MAPK pathways in PAH.
receptor protein serine/threonine kinase deficiency
BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGF? responses and altered cell mechanics.
receptor protein serine/threonine kinase deficiency
BMPR2 promotes fatty acid oxidation and protects white adipocytes from cell death in mice.
receptor protein serine/threonine kinase deficiency
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
receptor protein serine/threonine kinase deficiency
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
receptor protein serine/threonine kinase deficiency
Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-?B and MAPK signaling.
receptor protein serine/threonine kinase deficiency
Caspase-8 restricts natural killer cell accumulation during MCMV Infection.
receptor protein serine/threonine kinase deficiency
Clinical phenotype of a Chinese patient with RIPK1 deficiency due to novel mutation.
receptor protein serine/threonine kinase deficiency
Combination of IAP antagonist and IFN? activates novel caspase-10- and RIPK1-dependent cell death pathways.
receptor protein serine/threonine kinase deficiency
Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.
receptor protein serine/threonine kinase deficiency
Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo.
receptor protein serine/threonine kinase deficiency
Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling.
receptor protein serine/threonine kinase deficiency
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
receptor protein serine/threonine kinase deficiency
Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.
receptor protein serine/threonine kinase deficiency
Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases.
receptor protein serine/threonine kinase deficiency
Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable.
receptor protein serine/threonine kinase deficiency
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
receptor protein serine/threonine kinase deficiency
Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
receptor protein serine/threonine kinase deficiency
MLKL contributes to Western diet-induced liver injury through inhibiting autophagy.
receptor protein serine/threonine kinase deficiency
Myeloid tumor necrosis factor and heme oxygenase-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
receptor protein serine/threonine kinase deficiency
Necroptosis Signaling Promotes Inflammation, Airway Remodeling, and Emphysema in Chronic Obstructive Pulmonary Disease.
receptor protein serine/threonine kinase deficiency
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
receptor protein serine/threonine kinase deficiency
Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
receptor protein serine/threonine kinase deficiency
Receptor-interacting protein kinase 3 deficiency inhibits immune cell infiltration and attenuates organ injury in sepsis.
receptor protein serine/threonine kinase deficiency
RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome.
receptor protein serine/threonine kinase deficiency
RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.
receptor protein serine/threonine kinase deficiency
RIPK1 and RIPK3: critical regulators of inflammation and cell death.
receptor protein serine/threonine kinase deficiency
RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis.
receptor protein serine/threonine kinase deficiency
RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
receptor protein serine/threonine kinase deficiency
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
receptor protein serine/threonine kinase deficiency
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
receptor protein serine/threonine kinase deficiency
RIPK3 and Caspase-1/11 Are Necessary for Optimal Antigen-Specific CD8 T Cell Response Elicited by Genetically Modified Listeria monocytogenes.
receptor protein serine/threonine kinase deficiency
RIPK3 as a potential therapeutic target for Gaucher's disease.
receptor protein serine/threonine kinase deficiency
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
receptor protein serine/threonine kinase deficiency
Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury.
receptor protein serine/threonine kinase deficiency
RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury.
receptor protein serine/threonine kinase deficiency
RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis.
receptor protein serine/threonine kinase deficiency
Ripk3 regulates cardiac microvascular reperfusion injury: The role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-action/filopodia-based cellular migration.
receptor protein serine/threonine kinase deficiency
RIPK3-Mediated Necroptosis in Diabetic Cardiomyopathy Requires CaMKII Activation.
receptor protein serine/threonine kinase deficiency
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
receptor protein serine/threonine kinase deficiency
Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke.
receptor protein serine/threonine kinase deficiency
Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis.
receptor protein serine/threonine kinase deficiency
Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
receptor protein serine/threonine kinase deficiency
Survival function of the FADD-CASPASE-8-cFLIP(L) complex.
receptor protein serine/threonine kinase deficiency
TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation.
receptor protein serine/threonine kinase deficiency
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
receptor protein serine/threonine kinase deficiency
TWEAK and RIPK1 mediate a second wave of cell death during AKI.
receptor protein serine/threonine kinase deficiency
Ubiquitination of RIPK1 regulates its activation mediated by TNFR1 and TLRs signaling in distinct manners.
receptor protein serine/threonine kinase deficiency
Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation.
receptor protein serine/threonine kinase deficiency
ZBP1/DAI Drives RIPK3-Mediated Cell Death Induced by IFNs in the Absence of RIPK1.
Rectal Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Renal Insufficiency, Chronic
BMP type I receptor inhibition attenuates endothelial dysfunction in mice with chronic kidney disease.
Reperfusion Injury
Analyzing Necroptosis Using an RIPK1 Kinase Inactive Mouse Model of TNF Shock.
Reperfusion Injury
Combined Knockout of RIPK3 and MLKL Reveals Unexpected Outcome in Tissue Injury and Inflammation.
Reperfusion Injury
Expression and genetic polymorphism of necroptosis related protein RIPK1 is correlated with severe hepatic ischemia-reperfusion injury and prognosis after hepatectomy in hepatocellular carcinoma patients.
Reperfusion Injury
Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8.
Reperfusion Injury
Loss of RIPK3 and Caspase-8 Augments Intrinsic Apoptosis in Tubular Epithelial Cell and promote Kidney Ischemia Reperfusion Injury.
Reperfusion Injury
Necroptotic-Apoptotic Regulation in an Endothelin-1 Model of Cerebral Ischemia.
Reperfusion Injury
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Reperfusion Injury
Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury.
Reperfusion Injury
Ripk3 regulates cardiac microvascular reperfusion injury: The role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-action/filopodia-based cellular migration.
Reperfusion Injury
Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury.
Retinal Degeneration
A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model.
Retinal Neovascularization
Remodeling retinal neovascularization by ALK1 gene transfection in vitro.
Retinoblastoma
Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Retinoblastoma
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
Rhabdomyosarcoma, Embryonal
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Rhinitis, Allergic
LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.
Rhinitis, Allergic, Seasonal
Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis.
ring-type e3 ubiquitin transferase deficiency
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
Salmonella Infections
Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome.
Sandhoff Disease
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Sarcoma
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Sarcoma
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Sarcoma, Avian
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Kaposi
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Schistosomiasis
Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis.
Scimitar Syndrome
Whole-exome sequencing identifies SGCD and ACVRL1 mutations associated with total anomalous pulmonary venous return (TAPVR) in Chinese population.
Scleroderma, Systemic
Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis.
Scleroderma, Systemic
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts.
Sepsis
Association of plasma level of high-mobility group box-1 with necroptosis and sepsis outcomes.
Sepsis
Association of Plasma Level of TNF-Related Apoptosis-Inducing Ligand with Severity and Outcome of Sepsis.
Sepsis
Distinct cell death markers identified in critical care patient survivors diagnosed with sepsis.
Sepsis
Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease.
Sepsis
N-3-oxododecanoyl homoserine lactone exacerbates endothelial cell death by inducing receptor-interacting protein kinase 1-dependent apoptosis.
Sepsis
Necroptosis Promotes Staphylococcus aureus Clearance by Inhibiting Excessive Inflammatory Signaling.
Sepsis
Necroptosis regulated proteins expression is an early prognostic biomarker in patient with sepsis: a prospective observational study.
Sepsis
P2X1, P2X4, and P2X7 Receptor Knock Out Mice Expose Differential Outcome of Sepsis Induced by ?-Haemolysin Producing Escherichia coli.
Sepsis
Plasma receptor interacting protein kinase-3 levels are associated with acute respiratory distress syndrome in sepsis and trauma: a cohort study.
Sepsis
Receptor-interacting protein kinase 3 deficiency inhibits immune cell infiltration and attenuates organ injury in sepsis.
Sepsis
RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome.
Sepsis
RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome.
Sepsis
RIPK3 collaborates with GSDMD to drive tissue injury in lethal polymicrobial sepsis.
Sepsis
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Sezary Syndrome
Loss of receptors for transforming growth factor beta in human T-cell malignancies.
Shock, Septic
Necroptosis regulated proteins expression is an early prognostic biomarker in patient with sepsis: a prospective observational study.
Skin Diseases
Transforming growth factor-beta receptor expression on human skin fibroblasts: dimeric complex formation of type I and type II receptors and identification of glycosyl phosphatidylinositol-anchored transforming growth factor-beta binding proteins.
Skin Diseases
When Beauty Is Skin Deep: Regulation of the Wound Response by Caspase-8, RIPK3, and the Inflammasome.
Small Cell Lung Carcinoma
Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines.
Small Cell Lung Carcinoma
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Spinal Cord Injuries
B-RAFV600E Inhibitor Dabrafenib Attenuates RIPK3-Mediated Necroptosis and Promotes Functional Recovery after Spinal Cord Injury.
Spinal Cord Injuries
Changes in Expression of Receptor-Interacting Protein Kinase 1 in Secondary Neural Tissue Damage Following Spinal Cord Injury.
Spinal Cord Injuries
Lysosomal damage after spinal cord injury causes accumulation of RIPK1 and RIPK3 proteins and potentiation of necroptosis.
Squamous Cell Carcinoma of Head and Neck
Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Squamous Cell Carcinoma of Head and Neck
Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.
Squamous Cell Carcinoma of Head and Neck
Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis.
Squamous Cell Carcinoma of Head and Neck
Identification of genetic alterations in the TGFbeta type II receptor gene promoter.
Squamous Cell Carcinoma of Head and Neck
Inhibition of TGF-beta1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases.
Squamous Cell Carcinoma of Head and Neck
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway.
Squamous Cell Carcinoma of Head and Neck
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
The Expression of Activin Receptor-like Kinase 1 in HNSCC.
ST Elevation Myocardial Infarction
Changes in plasma levels of RIPK1, RIPK3, and MLKL in patients with coronary atherosclerotic heart disease and its clinical predictive value.
ST Elevation Myocardial Infarction
Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention.
Starvation
BOTRYTIS-INDUCED KINASE1, a plasma membrane-localized receptor-like protein kinase, is a negative regulator of phosphate homeostasis in Arabidopsis thaliana.
Starvation
Smad-mediated transcription is required for transforming growth factor-beta 1-induced p57(Kip2) proteolysis in osteoblastic cells.
Status Epilepticus
Hydrogen Alleviates Necroptosis and Cognitive Deficits in Lithium-Pilocarpine Model of Status Epilepticus.
Stomach Neoplasms
Association between receptor interacting serine/threonine kinase 2 polymorphisms and gastric cancer susceptibility.
Stomach Neoplasms
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
Stomach Neoplasms
C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer.
Stomach Neoplasms
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Stomach Neoplasms
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
Stomach Neoplasms
Expression of transforming growth factor-beta receptor type II gene in gastric cancer cell lines.
Stomach Neoplasms
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
Stomach Neoplasms
Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
Stomach Neoplasms
miR-100-3p inhibits cell proliferation and induces apoptosis in human gastric cancer through targeting to BMPR2.
Stomach Neoplasms
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Stomach Neoplasms
Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer.
Stroke
Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.
Stroke
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Subarachnoid Hemorrhage
Inhibiting of RIPK3 attenuates early brain injury following subarachnoid hemorrhage: Possibly through alleviating necroptosis.
Syncope
Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: A case report.
Synostosis
New insights into the molecular mechanism of multiple synostoses syndrome (SYNS): Mutation within the GDF5 knuckle epitope causes noggin-resistance.
Synovitis
The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts.
Telangiectasia, Hereditary Hemorrhagic
12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndrome.
Telangiectasia, Hereditary Hemorrhagic
99mTc-MAA Pulmonary Scintigraphy in Hereditary Hemorrhagic Telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
A Case of Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.
Telangiectasia, Hereditary Hemorrhagic
A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10.
Telangiectasia, Hereditary Hemorrhagic
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
Telangiectasia, Hereditary Hemorrhagic
A novel ENG mutation causing impaired co-translational processing of endoglin associated with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
A novel mutation in ALK-1 causes hereditary hemorrhagic telangiectasia type 2.
Telangiectasia, Hereditary Hemorrhagic
A Novel Variant in the ACVRL1 Gene in a Patient with Cirrhosis and Hereditary Hemorrhagic Telangiectasia
Telangiectasia, Hereditary Hemorrhagic
A rare cause of fatal right ventricular cardiac decompensation.
Telangiectasia, Hereditary Hemorrhagic
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Telangiectasia, Hereditary Hemorrhagic
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK.
Telangiectasia, Hereditary Hemorrhagic
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
Telangiectasia, Hereditary Hemorrhagic
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
Telangiectasia, Hereditary Hemorrhagic
ALK-1 mutations in liver transplanted patients with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Alk1 controls arterial endothelial cell migration in lumenized vessels.
Telangiectasia, Hereditary Hemorrhagic
ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway.
Telangiectasia, Hereditary Hemorrhagic
Allelic dropout in the ENG gene, affecting the results of genetic testing in hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
An Intron Mutation in the ACVRL1 May Be Associated with a Transcriptional Regulation Defect in a Chinese Family with Hereditary Hemorrhagic Telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2.
Telangiectasia, Hereditary Hemorrhagic
Arteriovenous malformation in the adult mouse brain resembling the human disease.
Telangiectasia, Hereditary Hemorrhagic
Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Telangiectasia, Hereditary Hemorrhagic
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Telangiectasia, Hereditary Hemorrhagic
BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
Telangiectasia, Hereditary Hemorrhagic
BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Telangiectasia, Hereditary Hemorrhagic
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Telangiectasia, Hereditary Hemorrhagic
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Telangiectasia, Hereditary Hemorrhagic
Casein kinase 2{beta} as a novel enhancer of activin-like receptor-1 signaling.
Telangiectasia, Hereditary Hemorrhagic
Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
Telangiectasia, Hereditary Hemorrhagic
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Clinical features and mutations in the ENG, ACVRL1, and SMAD4 genes in Korean patients with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2).
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasia, Hereditary Hemorrhagic
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Telangiectasia, Hereditary Hemorrhagic
Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.
Telangiectasia, Hereditary Hemorrhagic
Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients.
Telangiectasia, Hereditary Hemorrhagic
Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
Telangiectasia, Hereditary Hemorrhagic
ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Evidence for the founder effect of a novel ACVRL1 splice-site mutation in Hungarian hereditary hemorrhagic telangiectasia families.
Telangiectasia, Hereditary Hemorrhagic
Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.
Telangiectasia, Hereditary Hemorrhagic
Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by Hereditary Hemorrhagic Telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Generation and genetic repair of 2 iPSC clones from a patient bearing a heterozygous c.1120del18 mutation in the ACVRL1 gene leading to Hereditary Hemorrhagic Telangiectasia (HHT) type 2.
Telangiectasia, Hereditary Hemorrhagic
Generation of mice with a conditional and reporter allele for Tmem100.
Telangiectasia, Hereditary Hemorrhagic
Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
Telangiectasia, Hereditary Hemorrhagic
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Telangiectasia, Hereditary Hemorrhagic
Genotype-Phenotype Correlations in Children with HHT.
Telangiectasia, Hereditary Hemorrhagic
Global gene expression profiling of telangiectasial tissue from patients with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Telangiectasia, Hereditary Hemorrhagic
Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality.
Telangiectasia, Hereditary Hemorrhagic
Hereditary hemorrhagic telangiectasia type 1 and 2 mutations in Finland.
Telangiectasia, Hereditary Hemorrhagic
Hereditary Hemorrhagic Telangiectasia: Breakpoint Characterization of a Novel Large Deletion in ACVRL1 Suggests the Causing Mechanism.
Telangiectasia, Hereditary Hemorrhagic
Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.
Telangiectasia, Hereditary Hemorrhagic
Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.
Telangiectasia, Hereditary Hemorrhagic
Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1.
Telangiectasia, Hereditary Hemorrhagic
Identification of a Novel ACVRL1 Gene Mutation (c.100T>A, p.Cys34Ser) in a Japanese Patient with Possible Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease).
Telangiectasia, Hereditary Hemorrhagic
Identifying common genetic variants by high-resolution melting.
Telangiectasia, Hereditary Hemorrhagic
Idiopathic pulmonary hypertension: what did we learn from genes?
Telangiectasia, Hereditary Hemorrhagic
Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.
Telangiectasia, Hereditary Hemorrhagic
Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex.
Telangiectasia, Hereditary Hemorrhagic
Matrix Gla protein deficiency causes arteriovenous malformations in mice.
Telangiectasia, Hereditary Hemorrhagic
Minimal homozygous endothelial deletion of Eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse.
Telangiectasia, Hereditary Hemorrhagic
Multiple Sequence Variants in Hereditary Hemorrhagic Telangiectasia Cases. Illustration of Complexity in Molecular Diagnostic Interpretation.
Telangiectasia, Hereditary Hemorrhagic
Mutation analysis in Norwegian families with hereditary hemorrhagic telangiectasia: founder mutations in ACVRL1.
Telangiectasia, Hereditary Hemorrhagic
Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families.
Telangiectasia, Hereditary Hemorrhagic
Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
Telangiectasia, Hereditary Hemorrhagic
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Telangiectasia, Hereditary Hemorrhagic
Non-invasive CT screening for pulmonary arteriovenous malformations in children with confirmed hereditary hemorrhagic telangiectasia: Results from two pediatric centers.
Telangiectasia, Hereditary Hemorrhagic
Novel mutation c.263A>G in the ACVRL1 gene in a Japanese patient with hereditary hemorrhagic telangiectasia 2.
Telangiectasia, Hereditary Hemorrhagic
Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.
Telangiectasia, Hereditary Hemorrhagic
Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks.
Telangiectasia, Hereditary Hemorrhagic
Novel Protein Interactions with Endoglin and Activin Receptor-like Kinase 1: Potential Role in Vascular Networks.
Telangiectasia, Hereditary Hemorrhagic
Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models Of Hereditary Hemorrhagic Telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT.
Telangiectasia, Hereditary Hemorrhagic
Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Pulmonary arterial hypertension as the first manifestation in a patient with hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
Telangiectasia, Hereditary Hemorrhagic
Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.
Telangiectasia, Hereditary Hemorrhagic
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
Telangiectasia, Hereditary Hemorrhagic
Reduction of endoglin receptor impairs mononuclear cell-migration.
Telangiectasia, Hereditary Hemorrhagic
Regulation of ALK-1 signaling by the nuclear receptor LXRbeta.
Telangiectasia, Hereditary Hemorrhagic
Research on potential biomarkers in hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia.
Telangiectasia, Hereditary Hemorrhagic
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
Telangiectasia, Hereditary Hemorrhagic
SMAD4 Deficiency Leads to Development of Arteriovenous Malformations in Neonatal and Adult Mice.
Telangiectasia, Hereditary Hemorrhagic
Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
Telangiectasia, Hereditary Hemorrhagic
Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
Telangiectasia, Hereditary Hemorrhagic
The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.
Telangiectasia, Hereditary Hemorrhagic
The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
Telangiectasia, Hereditary Hemorrhagic
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Telangiectasia, Hereditary Hemorrhagic
Thoracic endografting in a patient with hereditary hemorrhagic telangiectasia presenting with a descending thoracic aneurysm.
Telangiectasia, Hereditary Hemorrhagic
Three novel mutations in the activin receptor-like kinase 1 (ALK-1) gene in hereditary hemorrhagic telangiectasia type 2 in Brazilian patients.
Telangiectasia, Hereditary Hemorrhagic
Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders.
Telangiectasia, Hereditary Hemorrhagic
Transforming growth factor-betas and vascular disorders.
Telangiectasia, Hereditary Hemorrhagic
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
Telangiectasia, Hereditary Hemorrhagic
VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.
Telangiectasia, Hereditary Hemorrhagic
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
Telangiectasia, Hereditary Hemorrhagic
[Clinical features and genetic screening of hereditary hemorrhagic telangiectasia].
Telangiectasia, Hereditary Hemorrhagic
[Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide].
Telangiectasia, Hereditary Hemorrhagic
[Gene diagnosis and treatment of hereditary hemorrhagic telangiectasia with epistaxis as its main symptom].
Telangiectasia, Hereditary Hemorrhagic
[Gene identification in a family of hereditary hemorrhagic telangiectasia].
Telangiectasia, Hereditary Hemorrhagic
[Hereditary hemorrhagic telangiectasia resulted from a nonsense mutation Arg479 Stop in the ALK-1 gene.]
Telangiectasia, Hereditary Hemorrhagic
[Liver involvement in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Report of one case and review of the literature.]
Telangiectasia, Hereditary Hemorrhagic
[Mutations of ACVRL1 gene in a pedigree with hereditary hemorrhagic telangiectasia]
Telangiectasis
12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndrome.
Telangiectasis
A Case of Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.
Telangiectasis
A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1.
Telangiectasis
A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10.
Telangiectasis
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
Telangiectasis
A novel ENG mutation causing impaired co-translational processing of endoglin associated with hereditary hemorrhagic telangiectasia.
Telangiectasis
A novel mutation in ALK-1 causes hereditary hemorrhagic telangiectasia type 2.
Telangiectasis
A Novel Variant in the ACVRL1 Gene in a Patient with Cirrhosis and Hereditary Hemorrhagic Telangiectasia
Telangiectasis
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.
Telangiectasis
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
Telangiectasis
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Telangiectasis
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK.
Telangiectasis
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
Telangiectasis
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
Telangiectasis
ALK-1 mutations in liver transplanted patients with hereditary hemorrhagic telangiectasia.
Telangiectasis
Allelic dropout in the ENG gene, affecting the results of genetic testing in hereditary hemorrhagic telangiectasia.
Telangiectasis
Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia.
Telangiectasis
An Intron Mutation in the ACVRL1 May Be Associated with a Transcriptional Regulation Defect in a Chinese Family with Hereditary Hemorrhagic Telangiectasia.
Telangiectasis
Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2.
Telangiectasis
Arteriovenous malformation in the adult mouse brain resembling the human disease.
Telangiectasis
Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Telangiectasis
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Telangiectasis
Bioinformatic analysis of pathogenic missense mutations of activin receptor like kinase 1 ectodomain.
Telangiectasis
BMP and activin type-II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
Telangiectasis
BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
Telangiectasis
BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia.
Telangiectasis
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
Telangiectasis
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Telangiectasis
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Telangiectasis
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Telangiectasis
Casein kinase 2{beta} as a novel enhancer of activin-like receptor-1 signaling.
Telangiectasis
Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia.
Telangiectasis
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
Telangiectasis
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
Telangiectasis
Clinical features and mutations in the ENG, ACVRL1, and SMAD4 genes in Korean patients with hereditary hemorrhagic telangiectasia.
Telangiectasis
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Telangiectasis
Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia.
Telangiectasis
Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2).
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia.
Telangiectasis
DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population.
Telangiectasis
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Telangiectasis
Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.
Telangiectasis
Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.
Telangiectasis
Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia.
Telangiectasis
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Telangiectasis
Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction.
Telangiectasis
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
Telangiectasis
ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia.
Telangiectasis
Evidence for the founder effect of a novel ACVRL1 splice-site mutation in Hungarian hereditary hemorrhagic telangiectasia families.
Telangiectasis
Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia.
Telangiectasis
Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.
Telangiectasis
Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by Hereditary Hemorrhagic Telangiectasia.
Telangiectasis
Generation and genetic repair of 2 iPSC clones from a patient bearing a heterozygous c.1120del18 mutation in the ACVRL1 gene leading to Hereditary Hemorrhagic Telangiectasia (HHT) type 2.
Telangiectasis
Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
Telangiectasis
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Telangiectasis
Genome sequencing reveals a deep intronic splicing ACVRL1 mutation hotspot in Hereditary Haemorrhagic Telangiectasia.
Telangiectasis
Global gene expression profiling of telangiectasial tissue from patients with hereditary hemorrhagic telangiectasia.
Telangiectasis
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Telangiectasis
Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality.
Telangiectasis
Hereditary Hemorrhagic Telangiectasia: Breakpoint Characterization of a Novel Large Deletion in ACVRL1 Suggests the Causing Mechanism.
Telangiectasis
Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.
Telangiectasis
Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.
Telangiectasis
Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1.
Telangiectasis
Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia.
Telangiectasis
Identification of a Novel ACVRL1 Gene Mutation (c.100T>A, p.Cys34Ser) in a Japanese Patient with Possible Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease).
Telangiectasis
Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia.
Telangiectasis
Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.
Telangiectasis
Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex.
Telangiectasis
Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).
Telangiectasis
Minimal homozygous endothelial deletion of Eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse.
Telangiectasis
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Telangiectasis
Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients.
Telangiectasis
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia.
Telangiectasis
Multiple Sequence Variants in Hereditary Hemorrhagic Telangiectasia Cases. Illustration of Complexity in Molecular Diagnostic Interpretation.
Telangiectasis
Mutation analysis in Norwegian families with hereditary hemorrhagic telangiectasia: founder mutations in ACVRL1.
Telangiectasis
Mutations in endoglin and in activin receptor-like kinase 1 among Danish patients with hereditary haemorrhagic telangiectasia.
Telangiectasis
Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia.
Telangiectasis
Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.
Telangiectasis
Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families.
Telangiectasis
Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
Telangiectasis
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Telangiectasis
Non-invasive CT screening for pulmonary arteriovenous malformations in children with confirmed hereditary hemorrhagic telangiectasia: Results from two pediatric centers.
Telangiectasis
Novel human pathological mutations. Gene symbol: ACVRL1. Disease: haemorrhagic telangiectasia 2.
Telangiectasis
Novel mutation c.263A>G in the ACVRL1 gene in a Japanese patient with hereditary hemorrhagic telangiectasia 2.
Telangiectasis
Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.
Telangiectasis
Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks.
Telangiectasis
Novel Protein Interactions with Endoglin and Activin Receptor-like Kinase 1: Potential Role in Vascular Networks.
Telangiectasis
Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models Of Hereditary Hemorrhagic Telangiectasia.
Telangiectasis
Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT.
Telangiectasis
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
Telangiectasis
Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia.
Telangiectasis
Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.
Telangiectasis
Pulmonary arterial hypertension as the first manifestation in a patient with hereditary hemorrhagic telangiectasia.
Telangiectasis
Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene.
Telangiectasis
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
Telangiectasis
Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.
Telangiectasis
Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.
Telangiectasis
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
Telangiectasis
Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia.
Telangiectasis
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
Telangiectasis
SMAD4 Deficiency Leads to Development of Arteriovenous Malformations in Neonatal and Adult Mice.
Telangiectasis
SMAD4 gene mutation increases the risk of aortic dilation in patients with hereditary haemorrhagic telangiectasia.
Telangiectasis
Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
Telangiectasis
Stroke after prolonged air travel associated with a pulmonary arteriovenous malformation.
Telangiectasis
Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
Telangiectasis
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
Telangiectasis
The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.
Telangiectasis
The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
Telangiectasis
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Telangiectasis
Thoracic endografting in a patient with hereditary hemorrhagic telangiectasia presenting with a descending thoracic aneurysm.
Telangiectasis
Three novel mutations in the activin receptor-like kinase 1 (ALK-1) gene in hereditary hemorrhagic telangiectasia type 2 in Brazilian patients.
Telangiectasis
Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders.
Telangiectasis
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
Telangiectasis
VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.
Telangiectasis
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
Telangiectasis
[Analysis of molecular background of hereditary haemorrhagic telangiectasia--Rendu-Osler-Weber disease--preliminary results]
Telangiectasis
[Clinical features and genetic screening of hereditary hemorrhagic telangiectasia].
Telangiectasis
[Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide].
Telangiectasis
[Gene diagnosis and treatment of hereditary hemorrhagic telangiectasia with epistaxis as its main symptom].
Telangiectasis
[Genetic diagnostics of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)].
Telangiectasis
[Hereditary hemorrhagic telangiectasia resulted from a nonsense mutation Arg479 Stop in the ALK-1 gene.]
Telangiectasis
[Liver involvement in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Report of one case and review of the literature.]
Telangiectasis
[Mutations of ACVRL1 gene in a pedigree with hereditary hemorrhagic telangiectasia]
Testicular Neoplasms
Transforming growth factor-beta expression in human testicular neoplasms.
Thrombosis
Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis.
Thrombosis
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.
Thrombosis
Gene mutations associated with thrombosis detected by whole-exome sequencing in paroxysmal nocturnal hemoglobinuria.
Thrombosis
The necroptotic cell death pathway operates in megakaryocytes, but not in platelet synthesis.
Thyroid Carcinoma, Anaplastic
Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma.
Thyroid Neoplasms
Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells.
Thyroid Neoplasms
Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.
Tracheoesophageal Fistula
Anaplastic lymphoma of the cervical esophagus presenting as a tracheoesophageal fistula.
Triple Negative Breast Neoplasms
LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis.
Tuberculosis
The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth.
Tuberculosis
The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria.
ulp1 peptidase deficiency
Stromal Senp1 promotes mouse early folliculogenesis by regulating BMP4 expression.
Ureteral Obstruction
Arkadia-Smad7-mediated positive regulation of TGF-beta signaling in a rat model of tubulointerstitial fibrosis.
Ureteral Obstruction
Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis.
Ureteral Obstruction
Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-beta type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds.
Ureteral Obstruction
EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-?/Smad and ROS signaling.
Ureteral Obstruction
Transforming growth factor-beta receptor types I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction.
Urinary Bladder Neoplasms
Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase.
Urinary Bladder Neoplasms
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Uterine Cervical Neoplasms
Correction: RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Uterine Cervical Neoplasms
Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway.
Uterine Cervical Neoplasms
Low Necroptosis Process Predicts Poor Treatment Outcome of Human Papillomavirus Positive Cervical Cancers by Decreasing Tumor-Associated Macrophages M1 Polarization.
Uterine Cervical Neoplasms
RIPK1 polymorphisms alter the susceptibility to cervical Cancer among the Uyghur population in China.
Uterine Cervical Neoplasms
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Vascular Calcification
Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2.
Vascular Diseases
A potential role for Insulin resistance in experimental pulmonary hypertension.
Vascular Diseases
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Vascular Diseases
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK.
Vascular Diseases
BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease.
Vascular Diseases
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Vascular Diseases
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
Vascular Diseases
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Vascular Diseases
Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC.
Vascular Diseases
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Vascular Diseases
Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension.
Vascular Diseases
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Vascular Diseases
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
Vascular Diseases
PPAR?-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Vascular Diseases
Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.
Vascular Diseases
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
Vascular Diseases
The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.
Vascular Diseases
The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells.
Vascular Malformations
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
Vascular Malformations
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Vascular Malformations
Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia.
Vascular Malformations
Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia.
Vascular Malformations
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
Vascular Malformations
Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
Vascular Malformations
The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
Vascular System Injuries
Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension.
Vascular System Injuries
Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension.
Vascular System Injuries
Vascular injury triggers Krüppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene.
Vein of Galen Malformations
An ACVRL1 gene mutation presenting as vein of Galen malformation at prenatal diagnosis.
Venous Thrombosis
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.
Ventilator-Induced Lung Injury
RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury.
Ventricular Dysfunction, Right
Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency.
Virus Diseases
Necroptosis mediators RIPK3 and MLKL suppress intracellular Listeria replication independently of host cell killing.
Virus Diseases
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Virus Diseases
RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection.
Vitelliform Macular Dystrophy
Unveiling the interactions among BMPR-2, ALK-1 and 5-HTT genes in the pathophysiology of HAPE.
Vitiligo
RIPK1 regulates the survival of human melanocytes upon endoplasmic reticulum stress.
Vitreoretinopathy, Proliferative
[Expression of TGF-beta receptor II in periretinal membranes of proliferative vitreoretinopathy]
Vocal Cord Paralysis
Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.
Zika Virus Infection
The Nucleotide Sensor ZBP1 and Kinase RIPK3 Induce the Enzyme IRG1 to Promote an Antiviral Metabolic State in Neurons.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000028
LY364947
-
pH 7.5, 30°C, recombinant mutant T204D ALK5, inhibition of autophosphorylation
0.000038
LY566578
-
pH 7.5, 30°C, recombinant mutant T204D ALK5, inhibition of autophosphorylation
0.000037
LY580276
-
pH 7.5, 30°C, recombinant mutant T204D ALK5, inhibition of autophosphorylation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00005 - 0.0013
4(quinolin-4-yl)-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
Homo sapiens
-
IC50 of 0.00005-0.0013 mM
0.00003 - 0.000555
4-phenyl substituted pyrazole inhibitors
Homo sapiens
-
inhibitory potency of 4-phenyl substituted pyrazole derivatives, IC50 of 30-555 nM, overview
-
0.000005 - 0.0195
4-phenyl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
Homo sapiens
-
IC50 of 0.000005-0.0195 mM
0.00007
LY566578
Homo sapiens
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 70 nM, mechanism
0.00058
LY580276
Homo sapiens
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 580 nM, mechanism
0.000175
LY364947
Homo sapiens
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 175 nM, mechanism
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
from patients of German origin with tentative diagnosis of hereditary hemorrhagic telangiectasia
brenda
-
pancreatic Smad4 null cell line, expression of Smad2 and Smad3
brenda
-
breast carcinoma cell line, derived from malignant pleural effusions
brenda
-
breast carcinoma cell line, derived from malignant pleural effusions
brenda
-
breast Smad4 null cell line, expression of Smad2 and Smad3
brenda
-
diverse VACO cell lines, Smad4 null cell lines, expression analysis of Smad2, overview
brenda
-
pancreatic Smad4 null cell line, expression of Smad2 and Smad3
brenda
-
pancreatic Smad4 null cell line, expression of Smad2 and Smad3
brenda
high ALK7 expression level, co-expression of nodal in different gestational stages
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
reduction in SMAD7 can lead to increased sensitivity to suppressive effects of TGF-beta on hematopoiesis. SMAD7, a negative regulator of TGF-beta receptor I (TBRI) kinase is markedly decreased in a large meta-analysis of gene expression studies from myelodysplastic syndrome marrow derived CD34+ cells, SMAD7 protein is also significantly decreased in myelodysplastic syndrome marrow progenitors. The increased TGF-beta signaling due to SMAD7 reduction can be effectively inhibited by TBRI (ALK5 kinase) inhibitor LY-2157299
physiological function
SMAD7 is a negative regulator of TGF-beta receptor I (TBRI) kinase. The enzyme increases Smad7 via increased TGF-beta signaling
malfunction
malfunction
hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) is an autosomal dominant disorder which is clinically characterised by recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations, genetic linkage studies identify 2 genes primarily related to hereditary hemorrhagic telangiectasia: endoglin and activin receptor-like kinase 1, 10 different ACVRL1 mutations can be identified in 12 out of 41 hereditary hemorrhagic telangiectasia patients, including 2 deletions, 2 insertions, 1 splice site mutation and 5 missense mutations
malfunction
-
mutations in transforming growth factor-beta (TGF-beta) receptor superfamily members underlie conditions characterized by vascular dysplasia
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). TGFR1_HUMAN
503
2
55960
Swiss-Prot
Secretory Pathway (Reliability: 1)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
ALK5 is the intracellular domain of the transforming growth factor beta type-I receptor
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
phosphoprotein
-
ALK5 performs autophosphorylation, wild-type and mutant T204D enzymes
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
D89A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
E88A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
F82A
-
site-directed mutagenesis, the mutation slightly affects binding of actividin
H312Q
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
I70A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
K72A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
L381P
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
L40A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
L75A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
L90A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
M53A
-
site-directed mutagenesis, the mutation slightly affects binding of actividin
P77A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
P81A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
R479Q
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
R484Q
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
S38A
-
site-directed mutagenesis, the mutation slightly affects binding of actividin
T194D
V73A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
additional information
additional information
knockout of TBRI by shRNA suppression using a lentiviral construct leads to decreased smad2 activtaion and reverses the suppressive effects of TGF-beta on hematopoiesis, overview
additional information
-
construction of a truncated dominant negative ALK4 mutant
additional information
-
expression of HA-tagged wild-type ALK7 in rat FaO hepatoma cells and transiently of HA-tagged ALK mutant T194D in human Hep3B hepatoma cells using the adenovirus infection method, expression leads in both cases to an apoptosis-positive phenotype, expression of inactive ALK7 mutant K222R dos not cause an altered phenotype
additional information
-
functional co-expression of TGF-beta and the soluble intracellular domain of the TGF-beta type I receptor in murine mammary gland epithelial cells induces transdifferentiation of epithelial cells to mesenchymal cells, overview
additional information
ALK1 mutations cause hereditary hemorrhagic telangiectasia in association with pulmonary arterial hypertension, PAH, in patients, determination of polymorphisms in Japanese pulmonary arterial hypertension patients, phenotypes, overview
additional information
-
ALK1 mutations cause hereditary hemorrhagic telangiectasia in association with pulmonary arterial hypertension, PAH, in patients, determination of polymorphisms in Japanese pulmonary arterial hypertension patients, phenotypes, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant His-tagged transforming growth factor-beta type I receptor kinase domain mutant T204D from insect Sf9 cells by nickel affinity chromatography
-
recombinant His-tagged wild-type and mutant ALK5 from Spodoptera frugiperda Sf9 cells by nickel affinity chromatography
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
gene ALK5, transient recombinant expression of FLAG-tagged enzyme mutant T202D in HEKT293 cells
activin receptor-like kinase 1 gene, ALK1 is located on chromosome 12q13, DNA and amino acid sequence determination of wild-type and mutant enzymes, genotyping
ALK7, DNA and amino acid sequence determination and analysis, genetic organization, determination of several isoforms by alternative splicing of ALK7
co-expression and co-localization of ALK1 mutant Q201D and cytoplasmic PEG10-RF1 mutant YFP in COS-1 cells, expression of ALK1 and ALK5 with PEG10-RF1 in a two-hydrid system in Saccharomyces cerevisiae, overview
-
expression of HA-tagged wild-type ALK7 in rat FaO hepatoma cells and transiently of HA-tagged ALK mutant T194D in human Hep3B hepatoma cells using the adenovirus infection method, expression leads in both cases to an apoptosis-positive phenotype, expression of inactive ALK7 mutant K222R dos not cause an altered phenotype
-
expression of His-tagged transforming growth factor-beta type I receptor kinase domain mutant T204D in Spodoptera frugiperda Sf9 cells using the baculovirus infection system
-
expression of His-tagged wild-type and mutant ALK5 in Spodoptera frugiperda Sf9 cells using the baculovirus infection system
-
functional co-expression of TGF-beta and the soluble intracellular domain of the TGF-beta type I receptor in murine mammary gland epithelial cells and in mink lung epithelial cells inducing growth inhibition
-
surface expression of wild-type and mutant ALK4 type I receptors in HEK293T cells, expression of wild-type and mutant ALK4 type I receptors in mink lung epithelial cells, Mv1Lu cells
-
transient expression of wild-type and mutant enzymes in COS-7 cells, and in Min-6 and Hep-G2 cells
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
(1'R,5'S,6'S)-2-(3',5'-dibromo-1',6'-dihydroxy-4'-oxocyclohex-2'-enyl) acetonitrile has no effects on TGF-beta receptor synthesis
down-regulation of ALK1 in LX-2 cells by the herbal compound Cpd861, cells are treated with TGF-beta1 (5 ng/ml) Cpd861 (0.1 mg/ml), TGF-beta1 (5 ng/ml) plus Cpd861 (an extract of 10 herbs traditionally applied as chinese medicine, 5 ng/ml) for 24 h to investigate the effect of Cpd861 on the TGF-beta1/ALK1 pathway
-
reduction of endogenous ALK1 expression significantly attenuates BMP9-mediated phosphorylation of Smad1/5 and Smad2
-
the ALK1 gene is constitutively expressed in LX-2 cells and TGF-beta1 does not further increase its expression
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
medicine
therapeutic potential of TBRI inhibitors in myelodysplastic syndrome, MDS. The myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by cytologic dysplasia and ineffective hematopoiesis
pharmacology
enzyme inhibitor (1'R,5'S,6'S)-2-(3',5'-dibromo-1',6'-dihydroxy-4'-oxocyclohex-2'-enyl) acetonitrile is a potential therapeutic agent for fibrotic disease and cancer treatment
diagnostics
next to the Curaçao criteria, genetic analysis contributes as an essential tool to a reliable diagnosis of clinically affected hereditary hemorrhagic telangiectasia patients and clinically unsymptomatic hereditary hemorrhagic telangiectasia patients, thus helping to take early preventive measures even before the occurrence of first clinical symptoms, the PCR-SSP technique can facilitate this high task of genetic analysis in routine hereditary hemorrhagic telangiectasia diagnostics and underlines the importance of using molecular diagnosis for early identification of individuals carrying mutations and being at risk of vascular complications
medicine
the RIPK2 rs16900627 minor allele is significantly associated with the susceptibility to gastric cancer
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Ge, R.; Rajeev, V.; Subramanian, G.; Reiss, K.A.; Liu, D.; Higgins, L.; Joly, A.; Dugar, S.; Chakravarty, J.; Henson, M.; McEnroe, G.; Schreiner, G.; Reiss, M.
Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling
Biochem. Pharmacol.
68
41-50
2004
Homo sapiens
brenda
Ottesen, J.J.; Huse, M.; Sekedat, M.D.; Muir, T.W.
Semisynthesis of phosphovariants of Smad2 reveals a substrate preference of the activated TbetaRI kinase
Biochemistry
43
5698-5706
2004
Homo sapiens (P36897), Homo sapiens
brenda
Peng, S.B.; Yan, L.; Xia, X.; Watkins, S.A.; Brooks, H.B.; Beight, D.; Herron, D.K.; Jones, M.L.; Lampe, J.W.; McMillen, W.T.; Mort, N.; Sawyer, J.S.; Yingling, J.M.
Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition
Biochemistry
44
2293-2304
2005
Homo sapiens
brenda
Roberts, H.J.; Hu, S.; Qiu, Q.; Leung, P.C.; Caniggia, I.; Gruslin, A.; Tsang, B.; Peng, C.
Identification of novel isoforms of activin receptor-like kinase 7 (ALK7) generated by alternative splicing and expression of ALK7 and its ligand, Nodal, in human placenta
Biol. Reprod.
68
1719-1726
2003
Homo sapiens (Q8NER5), Homo sapiens
brenda
Sawyer, J.S.; Beight, D.W.; Britt, K.S.; Anderson, B.D.; Campbell, R.M.; Goodson, T.Jr.; Herron, D.K.; Li, H.Y.; McMillen, W.T.; Mort, N.; Parsons, S.; Smith, E.C.; Wagner, J.R.; Yan, L.; Zhang, F.; Yingling, J.M.
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain
Bioorg. Med. Chem. Lett.
14
3581-3584
2004
Homo sapiens, Mus musculus
brenda
Harrison, C.A.; Gray, P.C.; Koerber, S.C.; Fischer, W.; Vale, W.
Identification of a functional binding site for activin on the type I receptor ALK4
J. Biol. Chem.
278
21129-21135
2003
Homo sapiens
brenda
Kim, B.C.; van Gelder, H.; Kim, T.A.; Lee, H.J.; Baik, K.G.; Chun, H.H.; Lee, D.A.; Choi, K.S.; Kim, S.J.
Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells
J. Biol. Chem.
279
28458-28465
2004
Homo sapiens
brenda
Ungefroren, H.; Groth, S.; Ruhnke, M.; Kalthoff, H.; Fandrich, F.
Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta
J. Biol. Chem.
280
2644-2652
2005
Homo sapiens
brenda
Lux, A.; Beil, C.; Majety, M.; Barron, S.; Gallione, C.J.; Kuhn, H.M.; Berg, J.N.; Kioschis, P.; Marchuk, D.A.; Hafner, M.
Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1
J. Biol. Chem.
280
8482-8493
2005
Homo sapiens
brenda
Halder, S.K.; Beauchamp, R.D.; Datta, P.K.
A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers
Neoplasia
7
509-521
2005
Homo sapiens
brenda
Fink, S.P.; Mikkola, D.; Willson, J.K.V.; Markowitz, S.
TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines
Oncogene
22
1317-1323
2003
Homo sapiens
brenda
Watanabe, R.; Shen, Z.P.; Tsuda, K.; Yamada, Y.
Insulin gene is a target in activin receptor-like kinase 7 signaling pathway in pancreatic beta-cells
Biochem. Biophys. Res. Commun.
377
867-872
2008
Homo sapiens
brenda
Zhou, L.; Nguyen, A.N.; Sohal, D.; Ying Ma, J.; Pahanish, P.; Gundabolu, K.; Hayman, J.; Chubak, A.; Mo, Y.; Bhagat, T.D.; Das, B.; Kapoun, A.M.; Navas, T.A.; Parmar, S.; Kambhampati, S.; Pellagatti, A.; Braunchweig, I.; Zhang, Y.; Wickrema, A.; Medicherla, S.; Boultwood, J.; Platanias, L.C.; Higgins, L.S.
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS
Blood
112
3434-3443
2008
Homo sapiens (P36897)
brenda
Xu, Y.; Tabe, Y.; Jin, L.; Watt, J.; McQueen, T.; Ohsaka, A.; Andreeff, M.; Konopleva, M.
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells
Br. J. Haematol.
142
192-201
2008
Homo sapiens
brenda
Fujiwara, M.; Yagi, H.; Matsuoka, R.; Akimoto, K.; Furutani, M.; Imamura, S.; Uehara, R.; Nakayama, T.; Takao, A.; Nakazawa, M.; Saji, T.
Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension
Circ. J.
72
127-133
2008
Homo sapiens (P37023), Homo sapiens
brenda
Bueno, L.; de Alwis, D.P.; Pitou, C.; Yingling, J.; Lahn, M.; Glatt, S.; Troconiz, I.F.
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice
Eur. J. Cancer
44
142-150
2008
Homo sapiens
brenda
Zhao, S.; Ammanamanchi, S.; Brattain, M.; Cao, L.; Thangasamy, A.; Wang, J.; Freeman, J.W.
Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells
J. Biol. Chem.
283
11293-11301
2008
Homo sapiens
brenda
Xu, G.; Bernaudo, S.; Fu, G.; Lee, D.Y.; Yang, B.B.; Peng, C.
Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7
Mol. Biol. Cell
19
4968-4979
2008
Homo sapiens
brenda
Haneen, S.; Johanna, H.; Ulrich, G.; Jens, S.S.; Frank, R.; Karl, H.; Peter, B.
Mutation analysis of "Endoglin" and "Activin receptor-like kinase" genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique
BMC Med. Genet.
10
53
2009
Homo sapiens (P37023), Homo sapiens
brenda
Upton, P.D.; Davies, R.J.; Trembath, R.C.; Morrell, N.W.
Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells
J. Biol. Chem.
284
15794-15804
2009
Homo sapiens
brenda
Li, L.; Zhao, X.Y.; Wang, B.E.
Down-regulation of transforming growth factor beta 1/activin receptor-like kinase 1 pathway gene expression by herbal compound 861 is related to deactivation of LX-2 cells
World J. Gastroenterol.
14
2894-2899
2008
Homo sapiens
brenda
Zhou, L.; McMahon, C.; Bhagat, T.; Alencar, C.; Yu, Y.; Fazzari, M.; Sohal, D.; Heuck, C.; Gundabolu, K.; Ng, C.; Mo, Y.; Shen, W.; Wickrema, A.; Kong, G.; Friedman, E.; Sokol, L.; Mantzaris, I.; Mantzaris, G.; Pellagatti, A.; Boultwood, J.; Platanias, L.C.; Steidl, U.; Yan, L.; Yingling, J.M.; Lahn, M.M.
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase
Cancer Res.
71
955-963
2011
Homo sapiens (P36897)
brenda
Chen, C.L.; Kao, Y.C.; Yang, P.H.; Sung, P.J.; Wen, Z.H.; Chen, J.J.; Huang, Y.B.; Chen, P.Y.
A small dibromotyrosine derivative purified from Pseudoceratina sp. suppresses TGF-beta responsiveness by inhibiting TGF-beta type I receptor serine/threonine kinase activity
J. Cell. Biochem.
117
2800-2814
2016
Homo sapiens (P36897)
brenda
Ota, M.; Tahara, T.; Otsuka, T.; Jing, W.; Nomura, T.; Hayashi, R.; Shimasaki, T.; Nakamura, M.; Shibata, T.; Arisawa, T.
Association between receptor interacting serine/threonine kinase 2 polymorphisms and gastric cancer susceptibility
Oncol. Lett.
15
3772-3778
2018
Homo sapiens (O43353)
brenda
EXTERNAL LINKS (specific for EC-Number 2.7.11.30)
Transporter Classification Database (TCDB): 8.A.23.1.27
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
